
<html lang="en"     class="pb-page"  data-request-id="a6c90876-e667-459d-805f-99a67a216583"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00995;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-19"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor" /></meta><meta name="dc.Creator" content="Bryan K.  Chan" /></meta><meta name="dc.Creator" content="Emily J.  Hanan" /></meta><meta name="dc.Creator" content="Krista K.  Bowman" /></meta><meta name="dc.Creator" content="Marian C.  Bryan" /></meta><meta name="dc.Creator" content="Daniel  Burdick" /></meta><meta name="dc.Creator" content="Emily  Chan" /></meta><meta name="dc.Creator" content="Yuan  Chen" /></meta><meta name="dc.Creator" content="Saundra  Clausen" /></meta><meta name="dc.Creator" content="Trisha  Dela Vega" /></meta><meta name="dc.Creator" content="Jennafer  Dotson" /></meta><meta name="dc.Creator" content="Charles  Eigenbrot" /></meta><meta name="dc.Creator" content="Richard L.  Elliott" /></meta><meta name="dc.Creator" content="Robert A.  Heald" /></meta><meta name="dc.Creator" content="Philip S.  Jackson" /></meta><meta name="dc.Creator" content="Jamie D.  Knight" /></meta><meta name="dc.Creator" content="Hank  La" /></meta><meta name="dc.Creator" content="Michael D.  Lainchbury" /></meta><meta name="dc.Creator" content="Shiva  Malek" /></meta><meta name="dc.Creator" content="Hans E.  Purkey" /></meta><meta name="dc.Creator" content="Gabriele  Schaefer" /></meta><meta name="dc.Creator" content="Stephen  Schmidt" /></meta><meta name="dc.Creator" content="Eileen M.  Seward" /></meta><meta name="dc.Creator" content="Steve  Sideris" /></meta><meta name="dc.Creator" content="Lily  Shao" /></meta><meta name="dc.Creator" content="Shumei  Wang" /></meta><meta name="dc.Creator" content="Siew Kuen  Yeap" /></meta><meta name="dc.Creator" content="Ivana  Yen" /></meta><meta name="dc.Creator" content="Christine  Yu" /></meta><meta name="dc.Creator" content="Timothy P.  Heffron" /></meta><meta name="dc.Description" content="Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point ..." /></meta><meta name="Description" content="Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 12, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00995" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00995" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00995" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00995" /></link>
        
    
    

<title>Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00995" /></meta><meta property="og:title" content="Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0020.jpeg" /></meta><meta property="og:description" content="Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point mutation (T790M) in the inhibitor binding site has been linked to the acquired resistance against those first generation therapeutics. Herein, we describe the lead optimization of a series of reversible, pan-mutant (L858R, del746–750, T790M/L858R, and T790M/del746–750) EGFR inhibitors. By use of a noncovalent double mutant (T790M/L858R and T790M/del746–750) selective EGFR inhibitor (2) as a starting point, activities against the single mutants (L858R and del746–750) were introduced through a series of structure-guided modifications. The in vitro ADME-PK properties of the lead molecules were further optimized through a number of rational structural changes. The resulting inhibitor (21) exhibited excellent cellular activity against both the single and double mutants of EGFR, demonstrating target engagement in vivo and ADME-PK properties that are suitable for further evaluation. The reversible, noncovalent inhibitors described complement the covalent pan-mutant EGFR inhibitors that have shown encouraging results in recent clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00995"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00995">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00995&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00995&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00995&amp;href=/doi/10.1021/acs.jmedchem.6b00995" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 9080-9093</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00976" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00993" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryan+K.++Chan">Bryan K. Chan</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily+J.++Hanan">Emily J. Hanan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Krista+K.++Bowman">Krista K. Bowman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marian+C.++Bryan">Marian C. Bryan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Burdick">Daniel Burdick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily++Chan">Emily Chan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuan++Chen">Yuan Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Saundra++Clausen">Saundra Clausen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Trisha++Dela+Vega">Trisha Dela Vega</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennafer++Dotson">Jennafer Dotson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Eigenbrot">Charles Eigenbrot</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+L.++Elliott">Richard L. Elliott</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Heald">Robert A. Heald</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+S.++Jackson">Philip S. Jackson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jamie+D.++Knight">Jamie D. Knight</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hank++La">Hank La</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Lainchbury">Michael D. Lainchbury</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shiva++Malek">Shiva Malek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hans+E.++Purkey">Hans E. Purkey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gabriele++Schaefer">Gabriele Schaefer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Schmidt">Stephen Schmidt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eileen+M.++Seward">Eileen M. Seward</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Sideris">Steve Sideris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lily++Shao">Lily Shao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shumei++Wang">Shumei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Siew+Kuen++Yeap">Siew Kuen Yeap</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ivana++Yen">Ivana Yen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Yu">Christine Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+P.++Heffron">Timothy P. Heffron</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Departments of <sup>†</sup>Discovery Chemistry, <sup>‡</sup>Structural Biology, <sup>§</sup>Drug Metabolism and Pharmacokinetics, <sup>∥</sup>Biochemical and Cellular Pharmacology, <sup>⊥</sup>Molecular Oncology, <sup>#</sup>Research Oncology, and <sup>∇</sup>Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">○</span> <span class="aff-text">Charles River Laboratories, 7/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#bdded5dcd393dfcfc4dcd3fddad8d3d893ded2d0"><span class="__cf_email__" data-cfemail="73101b121d5d11010a121d3314161d165d101c1e">[email protected]</span></a>. Phone: 1-650-225-1000.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00995&amp;href=/doi/10.1021%2Facs.jmedchem.6b00995" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 9080–9093</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 26, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 July 2016</li><li><span class="item_label"><b>Published</b> online</span>12 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00995" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00995</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9080%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBryan%2BK.%2BChan%252C%2BEmily%2BJ.%2BHanan%252C%2BKrista%2BK.%2BBowman%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D19%26contentID%3Dacs.jmedchem.6b00995%26title%3DDiscovery%2Bof%2Ba%2BNoncovalent%252C%2BMutant-Selective%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitor%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9093%26publicationDate%3DOctober%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00995"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3098</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00995" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;K. Chan&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;J. Hanan&quot;},{&quot;first_name&quot;:&quot;Krista&quot;,&quot;last_name&quot;:&quot;K. Bowman&quot;},{&quot;first_name&quot;:&quot;Marian&quot;,&quot;last_name&quot;:&quot;C. Bryan&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Burdick&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Yuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Saundra&quot;,&quot;last_name&quot;:&quot;Clausen&quot;},{&quot;first_name&quot;:&quot;Trisha&quot;,&quot;last_name&quot;:&quot;Dela Vega&quot;},{&quot;first_name&quot;:&quot;Jennafer&quot;,&quot;last_name&quot;:&quot;Dotson&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Eigenbrot&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;L. Elliott&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Heald&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;S. Jackson&quot;},{&quot;first_name&quot;:&quot;Jamie&quot;,&quot;last_name&quot;:&quot;D. Knight&quot;},{&quot;first_name&quot;:&quot;Hank&quot;,&quot;last_name&quot;:&quot;La&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Lainchbury&quot;},{&quot;first_name&quot;:&quot;Shiva&quot;,&quot;last_name&quot;:&quot;Malek&quot;},{&quot;first_name&quot;:&quot;Hans&quot;,&quot;last_name&quot;:&quot;E. Purkey&quot;},{&quot;first_name&quot;:&quot;Gabriele&quot;,&quot;last_name&quot;:&quot;Schaefer&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Schmidt&quot;},{&quot;first_name&quot;:&quot;Eileen&quot;,&quot;last_name&quot;:&quot;M. Seward&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Sideris&quot;},{&quot;first_name&quot;:&quot;Lily&quot;,&quot;last_name&quot;:&quot;Shao&quot;},{&quot;first_name&quot;:&quot;Shumei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Siew&quot;,&quot;last_name&quot;:&quot;Kuen Yeap&quot;},{&quot;first_name&quot;:&quot;Ivana&quot;,&quot;last_name&quot;:&quot;Yen&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;P. Heffron&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;9080-9093&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00995&quot;},&quot;abstract&quot;:&quot;Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point mutation (T790M) in the inhibitor binding site has been linked to the acquired resistance against those first generation therapeutics. Herein, we describe the lead optimization of a series of reversible, pan-mutant (L858R, del746–750, T790M/L858R, and T790M/del746–750) EGFR inhibitors. By use of a noncovalent double mutant (T790M/L858R and T790M/del746–750) selective EGFR inhibitor (2) as a starting point, activities against the single mutants (L858R and del746–750) were introduced through a series of structure-guided modifications. The in vitro ADME-PK properties of the lead molecules were further optimized through a number of rational structural changes. The resulting inhibitor (21) exhibited excellent cellular activity against both the single and double mutants of EGFR, demonstrating target engagement in vivo and&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00995&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00995" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00995&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00995" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00995&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00995" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00995&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00995&amp;href=/doi/10.1021/acs.jmedchem.6b00995" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00995" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00995" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00995%26sid%3Dliteratum%253Aachs%26pmid%3D27564586%26genre%3Darticle%26aulast%3DChan%26date%3D2016%26atitle%3DDiscovery%2Bof%2Ba%2BNoncovalent%252C%2BMutant-Selective%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D19%26spage%3D9080%26epage%3D9093%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/jmcmar.2016.59.issue-19/20161013/jmcmar.2016.59.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant positive non-small-cell lung cancer. A secondary point mutation (T790M) in the inhibitor binding site has been linked to the acquired resistance against those first generation therapeutics. Herein, we describe the lead optimization of a series of reversible, pan-mutant (L858R, del<sub>746–750,</sub> T790M/L858R, and T790M/del<sub>746–750</sub>) EGFR inhibitors. By use of a noncovalent double mutant (T790M/L858R and T790M/del<sub>746–750</sub>) selective EGFR inhibitor (<b>2</b>) as a starting point, activities against the single mutants (L858R and del<sub>746–750</sub>) were introduced through a series of structure-guided modifications. The in vitro ADME-PK properties of the lead molecules were further optimized through a number of rational structural changes. The resulting inhibitor (<b>21</b>) exhibited excellent cellular activity against both the single and double mutants of EGFR, demonstrating target engagement in vivo and ADME-PK properties that are suitable for further evaluation. The reversible, noncovalent inhibitors described complement the covalent pan-mutant EGFR inhibitors that have shown encouraging results in recent clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58146" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58146" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The role of activating mutants of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) is well-documented.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1-5)</a> The most common activating mutants, the point mutation L858R or deletions within exon 19 (del<sub>746–750</sub>), increase EGFR-driven cell proliferation and survival. The first generation EGFR inhibitors (erlotinib and gefitinib) that target those activating mutants have demonstrated a remarkable initial rate of clinical response in the treatment of EGFR-mutated NSCLC.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6-10)</a> Additionally, a number of second-generation EGFR inhibitors that covalently target the Cys797 residue within the EGFR ATP binding site have been reported.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> While both first and second generation EGFR inhibitors demonstrated clinical efficacy, this efficacy is accompanied by skin and gastrointestinal toxicities that are believed to be associated with their inhibitory activity toward the wild type form of EGFR (wtEGFR).</div><div class="NLM_p">In addition, acquired resistance against these therapeutic agents follows.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16">(12-16)</a> Approximately 60% of the acquired resistance arises from a secondary point mutation of the gatekeeper residue Thr790 to methionine (T790M) within the EGFR kinase domain.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17-19)</a> This mutation, while maintaining catalytic function of the enzyme, reduces the inhibitory effect of erlotinib and gefitinib by occluding part of the binding site for these molecules while simultaneously increasing the kinase’s affinity for ATP.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24">(20-24)</a></div><div class="NLM_p">Recently, promising clinical results have been reported for the third generation inhibitors (osimertinib and rociletinib) that were designed to covalently inhibit both the activating mutations and the T790M resistance mutation while sparing wtEGFR.<a onclick="showRef(event, 'ref16 ref25 ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref16 ref25 ref26 ref27 ref28 ref29 ref30">(16, 25-30)</a> These results have led to the FDA approval of osimertinib for the treatment of patients with metastatic EGFR T790M-positive NSCLC who have progressed on or after other EGFR-blocking therapies. Despite this remarkable advance, clinical cases of the Cys797 to serine point mutation (C797S) conferring resistance to covalent inhibitors by eliminating the point of covalent modification have recently been reported.<a onclick="showRef(event, 'ref16 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref16 ref31 ref32 ref33">(16, 31-33)</a> Anticipating such a resistance mechanism, it was our goal to identify a noncovalent, mutant selective EGFR inhibitor.</div><div class="NLM_p">We previously reported a series of potent and selective inhibitors of the resistance mutants of EGFR (<b>1</b> and <b>2</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> Aminopyrimidine inhibitors <b>1</b> and <b>2</b> demonstrated excellent biochemical potency against the T790M-L858R (TMLR) and T790M-del<sub>746–750</sub> (TMdel) resistance double mutants of EGFR. These molecules inhibit the T790M mutants with high selectivity over wtEGFR, which was appealing for safety considerations. However, <b>1</b> and <b>2</b> each lack biochemical inhibitory effects on the initial T790-containing single activating mutants of EGFR (L858R and del<sub>746–750</sub>). A similar T790M selectivity profile of <b>1</b> and <b>2</b> was also observed in cellular EGFR autophosphorylation (pEGFR) assays, comparing activity in the TMLR expressing (H1975) and TMdel expressing (PC9-ER) cell lines against activity in the del<sub>746–750</sub> expressing (PC9) and wtEGFR (H292) cell lines.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Reversible T790M Resistance Mutant-Selective Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0012.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="."><i>K</i>i<sub>app</sub> (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">TMLR</th><th class="colsep0 rowsep0" align="center" char=".">TMdel</th><th class="colsep0 rowsep0" align="center" char=".">L858R</th><th class="colsep0 rowsep0" align="center" char=".">del<sub>746–750</sub></th><th class="colsep0 rowsep0" align="center" char=".">wtEGFR</th><th class="colsep0 rowsep0" align="center" char=".">pEGFR H1975</th><th class="colsep0 rowsep0" align="center" char=".">pEGFR PC9-ER</th><th class="colsep0 rowsep0" align="center" char=".">pEGFR PC9</th><th class="colsep0 rowsep0" align="center" char=".">pEGFR H292</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">490</td><td class="colsep0 rowsep0" align="char" char=".">122</td><td class="colsep0 rowsep0" align="char" char=".">0.021</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">223</td><td class="colsep0 rowsep0" align="char" char=".">572</td><td class="colsep0 rowsep0" align="char" char=".">313</td><td class="colsep0 rowsep0" align="char" char=".">0.261</td><td class="colsep0 rowsep0" align="char" char=".">0.081</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Compound <b>1</b> was a 1:1 mixture of (<i>R</i>)-1-(6-((2-((3<i>R</i>,4<i>S</i>)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl)amino)-1-((<i>S</i>)-1,1,1-trifluoropropan-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethan-1-ol and (<i>R</i>)-1-(6-((2-((3<i>S</i>,4<i>R</i>)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl)amino)-1-((<i>S</i>)-1,1,1-trifluoropropan-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-2-yl)ethan-1-ol.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Compound <b>2</b> was a 1:1 mixture of (3<i>R</i>,4<i>S</i>)-3-fluoro-1-(4-((2-((<i>R</i>)-1-hydroxyethyl)-1-((<i>S</i>)-1,1,1-trifluoropropan-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-yl)amino)pyrimidin-2-yl)piperidin-4-ol and (3<i>S</i>,4<i>R</i>)-3-fluoro-1-(4-((2-((<i>R</i>)-1-hydroxyethyl)-1-((<i>S</i>)-1,1,1-trifluoropropan-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-yl)amino)pyrimidin-2-yl)piperidin-4-ol.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Biochemical assays. All <i>K</i><sub>i</sub> data measurements reported are the geometric mean values of at least two independent experiments.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Inhibition of EGFR autophosphorylation. All IC<sub>50</sub> data measurements reported are the geometric mean values of at least two independent experiments. H1975: double mutant TMLR cell line. PC9-ER: double mutant TMdel cell line. PC9: activating mutant del<sub>746–750</sub> EGFR cell line. H292: wild type EGFR cell line.</p></div></div></div><div class="NLM_p last">As reports indicate the importance of sustained inhibition of EGFR activating mutants beyond initial progression on first generation EGFR inhibitor therapy, we sought to improve upon <b>1</b> and <b>2</b> by incorporating inhibition of the activating single mutants of EGFR along with the T790M double mutants.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Given their attractive overall physicochemical profiles, high selectivity against wtEGFR, and our knowledge of their structure–activity relationships, the aminopyrimidine inhibitors (<b>1</b> and <b>2</b>) were chosen as the starting points toward a noncovalent, wtEGFR-sparing, pan-mutant EFGR inhibitor.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As previously described, the selectivity of <b>1</b> and <b>2</b> for the T790M mutants over wtEGFR and the activating mutants was attributed to the favorable hydrophobic interactions between the 4-alkoxypiperidine group and the side chain of the methionine gatekeeper (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Fluorine substitution at the 3-position of the piperidine further enhanced those favorable interactions and resulted in enhanced inhibition of the T790M mutants while sparing the activating single mutants. The 4-hydroxyl or 4-alkyoxy substitutions of the piperidine group were critical to potency as they form a hydrogen bonding interaction with the conserved, catalytic Lys745. In order to generate an inhibitor that exhibits activities against the T790M resistance double mutants as well as the activating single mutants of EGFR, we hypothesized that it would be necessary to identify a replacement for the T790M-selective piperidine motif.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0001.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) T790M selective inhibitor <b>3</b>. Absolute stereochemistry of all asymmetric centers is as shown. (B) Overlay of a model of <i>N</i>-alkylsulfonylpyrazole design (green) with X-ray structure of resistance mutant-selective inhibitor <b>3</b> complexed with EGFR TMLR double mutant (ligand, orange; protein, cyan; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>). Predicted hydrogen bond interactions are shown as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Through a library approach, a number of aliphatic amines were examined and found to be inadequate replacements for the piperidine group.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Significant loss of potency was typically observed. In parallel, we embarked on a structure-based design approach with the aim of identifying a replacement for the 4-alkoxypiperidine group that could engage Lys745 and the P-loop residue Phe723. Since those two residues are conserved among all EGFR forms, we hypothesized that engaging those residues could result in favorable binding interactions toward both T790- and T790M-carrying mutants.</div><div class="NLM_p">An examination of the X-ray structure of a representative T790M selective inhibitor (<b>3</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A) in the TMLR double mutant form of EGFR suggested that it would be desirable to position a hydrogen bond acceptor approximately five bond lengths distal from the pyrimidine ring in order to engage Lys745 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B). A number of aliphatic systems that satisfied this requirement were tested and yielded disappointing results.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Further modeling results suggested that an <i>N</i>-alkylsulfonylpyrazole would position a hydrogen bond acceptor, namely, the sulfonyl oxygen, within hydrogen bonding distance from the ammonium group of Lys745 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B). Furthermore, the terminal alkyl group would also be within the appropriate distance to engage the side chain of Phe723 via hydrophobic interactions.</div><div class="NLM_p">To test the hypothesis, compound <b>6</b> was synthesized using the simplified achiral azabenzimidazole moiety as a model system for synthetic ease (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compound <b>6</b> demonstrated either comparable or improved activity against the TMLR double mutant and TMdel double mutants of EFGR when compared to the previously optimized piperidine-based inhibitors <b>4</b> and <b>5</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Gratifyingly, compound <b>6</b> also showed improved potency against the L858R and del<sub>746–750</sub> single activating mutants. Expansion of the methylsulfonyl group to a cyclopropylsulfonyl group (<b>7</b>) further improved potency for all forms of EGFR. The increase in activity for the bulkier cyclopropyl analog could possibly be due to the increase in hydrophobic interactions or, more specifically, π-interactions between the partially sp<sup>2</sup>-hybridized cyclopropyl group and the π-face of the aromatic side chain of Phe723. The cyclopropylmethyl analog <b>8</b> showed reduced inhibitory activity against the TMLR double mutant, which we attribute to its inability to engage Lys745 in a hydrogen bonding interaction (the other mutant forms were not tested).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Piperidine Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0013.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0014.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Biochemical assays. All <i>K</i><sub>i</sub> data measurements reported are the geometric mean values of at least two independent experiments.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Racemic, relative stereochemistry as shown.</p></div></div><div></div></div><div class="NLM_p">An X-ray structure of <b>7</b> in the TMLR double mutant was obtained to confirm the binding mode of the inhibitor (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In line with the previously disclosed structures of the inhibitors within this series, the amino-azabenzimidazole forms two hydrogen bonds with the backbone of Gln791 and Met793 in the hinge region of the binding site.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> The pyrimidyl group of the inhibitor is positioned under the Met790 gatekeeper side chain and engages Thr854 via hydrogen bonding. The <i>N</i>-cyclopropylsulfonylpyrazole appears to engage the ammonium group of Lys745 via both the sulfonyl oxygen (3.0 Å) and the pyrazole nitrogen (3.0 Å). The cyclopropylsulfonyl motif is also situated to engage the phenyl side chain of Phe723 via hydrophobic interactions.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of <b>7</b> complexed with EGFR TMLR double mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCX">5HCX</a>). Predicted hydrogen bond interactions are shown as yellow dashed lines. Interatom distance is indicated by dashed purple lines with values in Å.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>7</b> demonstrated comparable in vitro metabolic stability and permeability properties to the corresponding hydroxypiperidine analog <b>4</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Most importantly, both <b>4</b> and <b>7</b> had acceptable predicted human clearance as extrapolated from in vitro liver microsome and hepatocyte data. Because of its promising overall profile, the <i>N</i>-cyclopropylsulfonylpyrazole group was used in subsequent optimization of the other parts of the molecule with the goal of further improving potency while maintaining acceptable ADME attributes.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro ADME Data for <b>4</b> and <b>7</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">liver microsome Cl<sub>hep</sub> H/R/M (mL min<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">hepatocyte Cl<sub>hep</sub> H/R/M (mL min<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">MDCK <i>P</i><sub>app</sub>(A–B) (×10<sup>–6</sup> cm s<sup>–1</sup>)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">5.2/12/76</td><td class="colsep0 rowsep0" align="left">9.0/11/69</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">7.7/20/70</td><td class="colsep0 rowsep0" align="left">4.0/17/49</td><td class="colsep0 rowsep0" align="left">21</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">H/R/M = human/rat/mouse.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">In vitro stability in cryopreserved hepatocytes.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">A–B, apical-to-basolateral. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details of assay errors and controls.</p></div></div></div><div class="NLM_p">The vector extending from the 3-position of the azabenzimidazole system had been underexplored to this point (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). To access this vector, replacement of the azabenzimidazole group with bioisosteric systems such as an azaindazole or azaindole would be required. Optimization on an azaindole system was first explored, as it was previously found to have potency comparable to that of the azabenzimidazole.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Due to the high lipophilicity of the scaffold in general (cLogP of <b>7</b> = 3.6) and a desire to reduce the metabolic liability of an electron-rich azaindole heterocycle, we first focused on polar electron-withdrawing substituents such as carboxamides.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Azaindole-3-carboxamide and Azaindazole-3-carboxamide SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0015.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0016.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Biochemical assays. All <i>K</i><sub>i</sub> data measurements reported are the geometric mean values of at least two independent experiments.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">A–B, apical-to-basolateral.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Aqueous kinetic solubility at pH 7.4.</p></div></div><div></div></div><div class="NLM_p">Gratifyingly, the 3-carboxamide azaindole <b>9</b> resulted in improved potency compared to azabenzimidazole <b>7</b> for both the T790- and T790M-carrying mutants of EGFR (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The gain in potency could possibly be attributed to water-mediated hydrogen bonding interactions between the carboxamide and the backbone carbonyl of Pro794 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). In the context of the 4-methoxypiperidine group (<b>10</b>), we again observed reduced potency for the L858R and del<sub>746–750</sub> single mutants relative to the T790M double mutants, suggesting that the 3-carboxamide group did not alter the mutant-selectivity of the inhibitor.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) X-ray structure of <b>13</b> in EGFR TMLR double mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCY">5HCY</a>). Predicted hydrogen bond interactions are shown as yellow dashed lines. (B) X-ray structure of <b>13</b> in EGFR TMLR double mutant with interaction surface shown. Color of surface indicates element (pink = oxygen; cyan = nitrogen; gray = carbon).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modest permeability was observed for <b>9</b>, possibly due to its high TPSA (150 Å<sup>2</sup>). Reducing the number of hydrogen bond donors in a molecule is a well-established strategy to improve permeability.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> We envisioned that conversion of the azaindole to an azaindazole could mask the NH functionality of the amide via an intramolecular hydrogen bond and therefore improve permeability. The 3-amidoazaindazole <b>11</b>, however, showed a significant loss of potency. With the increase in polarity, the azaindazole may have reduced favorable, hydrophobic contacts with the surrounding lipophilic residues (vide supra).</div><div class="NLM_p">Alternatively, the primary amide was replaced with a variety of the secondary amides to reduce the hydrogen bond donor count and improve aqueous solubility by deterring intermolecular hydrogen bonding (e.g., dimerization). Indeed, the oxetanyl (<b>12</b>) and tetrahydropyranyl (<b>13</b>) carboxamides demonstrated improved aqueous solubility. However, permeability remained modest. Possibly due to the combination of modest solubility and permeability, after a single oral dose of 100 mg/kg (MCT suspension) in mouse, plasma concentration of <b>13</b> was below the lowest level of quantification. The 3-carboxamide series was thus deprioritized. Nonetheless, the 3-amidoazaindole analogs demonstrated that significant potency gain can be achieved by substituting at the 3-position of the [6,5]-bicyclic scaffold.</div><div class="NLM_p">Close examination of the X-ray structure of <b>13</b> suggested that the C3-vector of the azaindole is situated under the lipophilic chain side of Leu718 in a narrow channel and three-dimensional steric bulk should only be tolerated beyond approximately two bond lengths from the azaindole core structure (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). To optimally occupy this space, a substitution would need to be lipophilic and structurally planar proximal to the [6,5]-bicyclic scaffold. Despite their apparent fit to this pocket, aryl motifs were considered to be undesirable due to their propensity to negatively impact aqueous solubility.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> We hypothesized that a dialkylamino motif should satisfy the requirements. To prevent further elevation of lipophilicity, heteroatoms were incorporated into the C3-substituents.</div><div class="NLM_p">Although the azaindole system had demonstrated excellent potency, we opted to focus on azaindazoles to study the C3-amine substitution to avoid the presence of a highly electron-rich 3-aminoazaindole system that could be a metabolic liability. In addition, given the excellent biochemical potency of the C3-substituted azaindole or azaindazole inhibitors, we opted to evaluate the potency of the compounds through the use of the cellular autophosphorylation assays (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. 3-Aminoazaindazole SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0017.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0018.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">Biochemical assays. All <i>K</i><sub>i</sub> data measurements reported are the geometric mean values of at least two independent experiments.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Inhibition of EGFR autophosphorylation. All IC<sub>50</sub> data measurements reported are the geometric mean values of at least two independent experiments. H1975: double mutant TMLR EGFR cell line. PC9-ER: double mutant TMdel EGFR cell line. PC9: activating mutant del<sub>746–750</sub> EGFR cell line. H292: wild type EGFR cell line.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">Metabolic clearance from human liver microsomes.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">Metabolic clearance from cryopreserved human hepatocytes.</p></div><div class="footnote" id="t5fn5"><sup>Table e</sup><p class="last">A–B, apical-to-basolateral.</p></div><div class="footnote" id="t5fn6"><sup>Table f</sup><p class="last">Kinetic solubility at pH 7.4.</p></div></div><div></div></div><div class="NLM_p">We previously found that 3-aminoazaindazoles had good activity against the TMLR double mutant, and that finding was recapitulated in the context of the <i>N</i>-cyclopropylsulfonylpyrazole (<b>14</b>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Expansion of the amino group to the morpholine (<b>15</b>) maintained cellular potency for both the activating del<sub>746–750</sub> mutant (PC9) and T790M double mutant (H1975 and PC9-ER) cell lines. The 4-hydroxypiperidine analog <b>16</b> was also tolerated by all mutant forms, while the hydroxymethylazetidine analog <b>17</b> provided improved potency. Introduction of the <i>gem</i>-dimethyl substitution (<b>18</b>) to sterically mask the hydrogen bond donor improved permeability. The tertiary alcohol <b>18</b> also showed improved hepatocyte stability relative to primary alcohol <b>17</b>. As predicted, replacement of the dialkylamino motif with a three-dimensional alkyl group (<b>19</b>) resulted in considerable loss in activity. At this point, compound <b>18</b> was chosen for further optimization due to its balanced pharmacological and ADME profiles.</div><div class="NLM_p">From our previous work on the azabenzimidazole series, we learned that further potency gains could be realized by expanding the <i>N</i>1-alkyl substitution of the azabenzimidazole system, given that it is a vector that extends toward the lipophilic ribose pocket in the EGFR ATP binding site that is lined with multiple hydrophobic residues (Leu844, Val726, Cys797).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> However, as shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, expansion of the isopropyl group to a <i>sec</i>-butyl group within the current series did not improve potency (<b>20</b> and <b>21</b> vs <b>18</b>). Gratifyingly, superior metabolic stability for the more lipophilic <b>21</b> was observed in both in vitro human liver microsome and hepatocyte assays. Improved metabolic stability was only observed for the <i>S</i>-enantiomer when compared to the isopropyl analog, which suggests that the <i>N</i>-alkyl substitution may have affected the binding and/or activity of cytochrome P450 in a specific manner. The fact that <b>21</b> demonstrated appealing predicted human metabolic stability and excellent potency led us to compare the potential of this molecule to the reported clinical inhibitors.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Optimization of <i>N</i>-Alkyl Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0019.gif" alt="" id="fx8" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">p-EGFR H1975</th><th class="colsep0 rowsep0" align="center" char=".">p-EGFR PC9-ER</th><th class="colsep0 rowsep0" align="center" char=".">p-EGFR PC9</th><th class="colsep0 rowsep0" align="center" char=".">p-EGFR H292</th><th class="colsep0 rowsep0" align="center">HLM<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a>/HHep<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">MDCK <i>P</i><sub>app</sub>(A–B) (×10<sup>–6</sup> cm s<sup>–1</sup>)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">K. sol. (μM)<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.032</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td><td class="colsep0 rowsep0" align="left">8.9/7.1</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>CH<sub>3</sub> (<i>R</i>)</td><td class="colsep0 rowsep0" align="char" char=".">0.040</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.057</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="left">9.9/7.8</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>CH<sub>3</sub> (<i>S</i>)</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="char" char=".">0.0080</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="left">3.8/2.7</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Inhibition of EGFR phosphorylation. All IC<sub>50</sub> data measurements reported are the geometric mean values of at least two independent experiments. H1975: double mutant TMLR EGFR cell line. PC9-ER: double mutant TMdel EGFR cell line. PC9: activating mutant del<sub>746–750</sub> EGFR cell line. H292: wild type EGFR cell line.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">In vitro stability in human liver microsomes.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">In vitro stability in cryopreserved human hepatocytes.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">A–B, apical-to-basolateral.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Kinetic solubility at pH 7.4.</p></div></div></div><div class="NLM_p">Compared to afatinib, an irreversible second generation EGFR inhibitor, <b>21</b> showed significantly reduced activity against wtEGFR (H292), which we believe to be important for safety considerations (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). We were very pleased to see that, like osimertinib and in contrast to the first generation EGFR inhibitors (erlotinib and getifinib), <b>21</b> demonstrated excellent potency against both the activating and resistant EGFR mutants in the cellular mechanistic assays, yet without requiring a covalent interaction. In addition, <b>21</b> demonstrated strong antiproliferative effect on the T790M mutant carrying H1975 cell line (IC<sub>50</sub> = 0.361 μM) and the single activating mutant PC9 cell line (IC<sub>50</sub> = 0.151 μM). Furthermore, compound <b>21</b> also showed good selectivity against other kinases when evaluated in a 225-kinase panel (12/225 kinases inhibited at >70% when tested at 0.1 μM, 61-fold over the TMLR <i>K</i><sub>i</sub> and 63-fold over the TMdel <i>K</i><sub>i</sub>; see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Comparison of Cellular Activity Profiles</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">pEGFR IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">H1975</th><th class="colsep0 rowsep0" align="center" char=".">PC9-ER</th><th class="colsep0 rowsep0" align="center" char=".">PC9</th><th class="colsep0 rowsep0" align="center" char=".">H292</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">0.218</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">afatinib</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.035</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="char" char=".">0.017</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td><td class="colsep0 rowsep0" align="char" char=".">0.483</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Inhibition of EGFR autophosphorylation. All IC<sub>50</sub> data measurements reported are the geometric mean values of at least two independent experiments. H1975: double mutant TMLR cell line. PC9-ER: double mutant TMdel cell line. PC9: activating mutant del<sub>746–750</sub> cell line. H292: wild type cell line.</p></div></div></div><div class="NLM_p">With the encouraging in vitro pharmacological profile, we elected to further evaluate <b>21</b> in vivo. The pharmacokinetic profile of <b>21</b> is outlined in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. In mouse, after intravenous and oral administration, the plasma clearance of <b>21</b> was determined to be 104 mL min<sup>–1</sup> kg<sup>–1</sup> with a bioavailability of 19%. In dogs, the plasma clearance was 13 mL min<sup>–1</sup> kg<sup>–1</sup> with an oral bioavailability of 30%. While high clearance at approximately liver blood flow was observed in mouse, the good correlation between in vivo clearance and in vitro clearance from liver microsomes in dog increased our confidence that <b>21</b> would have low clearance in human, as the in vitro clearance measured from human liver microsomes and hepatocytes was low.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Pharmacokinetic Parameters of <b>21</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">CL liver microsomes (mL min<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CL hepatocytes (mL min<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">iv Cl<sub>p</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)/<i>V</i><sub>ss</sub> (L kg<sup>-1</sup>)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">66.5</td><td class="colsep0 rowsep0" align="left">52.6</td><td class="colsep0 rowsep0" align="left">104/3.4</td><td class="colsep0 rowsep0" align="left">19<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">12.6</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">13/6.9</td><td class="colsep0 rowsep0" align="left">30<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Clearance determined from liver microsomes.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Clearance determined from cryopreserved hepatocytes.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Clp = plasma clearance. Compound dosed iv (mouse = 5 mg kg<sup>–1</sup>; dog = 1 mg kg<sup>–1</sup>) as a solution in 10/35/55 ethanol/PEG/water solution.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Compound dosed po (25 mg kg<sup>–1</sup>) as a solution in corn oil.</p></div><div class="footnote" id="t8fn5"><sup>e</sup><p class="last">Compound dosed po (2 mg kg<sup>–1</sup>) as a suspension in MCT.</p></div></div></div><div class="NLM_p">To examine its inhibitory effect on pEGFR levels in vivo, inhibitor <b>21</b> was studied in a mouse H1975 (TMLR) xenograft model (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). After a single oral dose of <b>21</b> at 50 mg/kg, free plasma concentrations of <b>21</b> at or exceeding the in vitro p-EGFR IC<sub>50</sub> of 0.027 μM were sustained over 8 h. When administered at 100 mg/kg, the coverage of p-EGFR IC<sub>50</sub> was extended to the last measured time point of 16 h postdose. Corresponding knockdown of p-EGFR and the downstream effectors pERK1/2 and AKT levels were observed at those time points, suggesting target engagement in vivo.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>21</b> was administered orally to H1975 tumor-bearing mice with either a 50 or 100 mg/kg single dose. Tumors were collected at indicated times, and phosphorylation of EGFR, ERK, AKT was determined using commercially available MSD assays. Bars represent individual animals (four animals per group). Dotted line on the free plasma concentration plot shows the in vitro H1975 p-EGFR IC<sub>50</sub>. Error bars represent the mean ± SD. Plasma concentrations of <b>21</b> were measured using liquid chromatography–tandem mass spectrometry assay, and free concentration was calculated using <i>F</i><sub>u</sub> of 0.009.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>1</b>–<b>5</b> were prepared using procedures previously described.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Compounds <b>6</b>–<b>8</b> were synthesized as outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Palladium-catalyzed coupling between chloroazabenzimidazole <b>22</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and 2-chloropyrimidin-4-amine afforded intermediate <b>23</b>. Suzuki coupling between intermediate <b>23</b> and the corresponding 4-pyrazole pinacol boronic esters <b>25</b>–<b>27</b> yielded <b>6</b>–<b>8</b>. The 4-pyrazole pinacol boronic esters <b>25</b>–<b>27</b> were prepared via the alkylation or sulfonylation of the commercially available 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>24</b>).</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 4-Amino-2-chloropyrimidine, Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 4 h, (26%); (b) <b>25</b>, <b>26</b>, or <b>27</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(Amphos)<sub>2</sub>Cl<sub>2</sub>, CH<sub>3</sub>CN, water, 100 °C, 3 h.</p></p></figure><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) For <b>25</b> and <b>26</b>, R-SO<sub>2</sub>Cl, NaH, DMF, rt, 5 h. (b) For <b>27</b>, bromomethylcyclopropane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 12 h (45%). (c) For <b>26</b>, 2-chloropyrimidin-4-amine, Na<sub>2</sub>CO<sub>3</sub>, Pd(Amphos)<sub>2</sub>Cl<sub>2</sub>, CH<sub>3</sub>CN, water, 100 °C, 2 h (85%).</p></p></figure><div class="NLM_p">Compounds <b>9</b>, <b>12</b>, and <b>13</b> were prepared according to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. A four-step sequence involving N-alkylation, Vilsmeier–Haack formylation, Pinnick oxidation, and amide bond formation efficiently advanced bromoazaindole <b>29</b> to intermediates <b>30</b>–<b>32</b>. Buchwald–Hartwig reactions between <b>30</b>–<b>32</b> and 2-chloropyrimidin-4-amine, followed by a Suzuki coupling with the pyrazole pinacol boronic ester <b>26</b>, afforded <b>9</b>, <b>12</b>, and <b>13</b>.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 2-Bromopropane, NaH, DMF, 0 °C to rt, 2 h (quant); (b) POCl<sub>3</sub>, DMF, rt, 2 h (80%); (c) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, water, <i>t</i>-BuOH, rt, 18 h (94%); (d) NH<sub>2</sub>R, HBTU, DIEA, DMF, rt, 40 min; (e) 4-amino-2-chloropyrimidine, Xantphos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C, 6 h; (f) <b>26</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(Amphos)<sub>2</sub>Cl<sub>2</sub>, CH<sub>3</sub>CN, water, 100 °C, 1 h.</p></p></figure><div class="NLM_p">Compounds <b>10</b> and <b>11</b> were synthesized according to <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Azaindole <b>38</b> was prepared via the four-step sequence described above starting from 6-chloro-5-azaindole (<b>36</b>). Iodination and alkylation of 6-chloro-5-azaindazole<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>37</b>), followed by methoxycarbonylation and amide bond synthesis, afforded azaindazole <b>39</b>. Palladium-catalyzed coupling of <b>38</b> or <b>39</b> with 2-(4-methoxypiperidin-1-yl)pyrimidin-4-amine yielded <b>10</b> and <b>11</b>.</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 2-Bromopropane, NaH, DMF, 0 °C to rt, 2 h (quant); (b) POCl<sub>3</sub>, DMF, rt, 2 h (80%); (c) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, water, <i>t</i>-BuOH, rt, 18 h (94%); (d) NH<sub>2</sub>R, HBTU, DIEA, DMF, rt, 40 min; (e) I<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h (quant); (f) 2-bromopropane, NaH, DMF, 0 °C to rt, 2 h (81%); (g) Pd(OAc)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>3</sub>OH, CO, 65 °C, 3 h (40%); (h) (i) (CH<sub>3</sub>)<sub>3</sub>SnOH, DCM, 60 °C, 4 h; (ii) NH<sub>4</sub>OH, HBTU, DIEA, DMF, rt, 20 min (25% over 2 steps); (i) 2-(4-methoxypiperidin-1-yl)pyrimidin-4-amine, chloro{[BrettPhos][2-(2-aminoethylphenyl]palladium(II)]}/[Brettphos] admixture, <i>t</i>-BuONa, <i>t</i>-BuOH, 120 °C, 3 h.</p></p></figure><div class="NLM_p">Compound <b>14</b> was prepared according to <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Iodination and N-alkylation of 6-bromo-5-azaindazole (<b>40</b>) afforded <b>41</b>. Installation of the protected 3-amino group was accomplished by a palladium-catalyzed coupling using benzophenone imine. Subsequent coupling with <b>28</b> followed by imine cleavage gave inhibitor <b>14</b>. Similarly, inhibitors <b>15</b>–<b>18</b>, <b>20</b>, and <b>21</b> were synthesized according to <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Iodination and N-alkylation of the commercially available <b>37</b> or <b>40</b> followed by copper-mediated amination yielded intermediates <b>43</b> and <b>44</b>. Subsequent palladium-catalyzed amination using the previously described aminopyrimidines <b>28</b> afforded the inhibitors <b>15</b>–<b>18</b>, <b>20</b>, and <b>21</b>. Chiral separation of <b>20</b> and <b>21</b> was achieved by using chiral supercritical fluid chromatography. Absolute stereochemistry of <b>21</b> was assigned by crystallography (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) I<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt (quant); (b) 2-bromopropane, NaH, DMF, 0 °C to rt (44%); (c) benzophenone imine, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, 1,4-dioxane, 90 °C (58%); (d) <b>28</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C (50%); (e) NH<sub>2</sub>OH·HCl, NaOAc, rt (14%).</p></p></figure><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) I<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) 2-bromopropane or 2-bromobutane, NaH, DMF, 0 °C to rt (quant); (c) HNR<sub>2</sub>, CuI, <span class="smallcaps smallerCapital">l</span>-proline, K<sub>2</sub>CO<sub>3</sub>, 90 °C, 3.5 h; (d) <b>28</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, XPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C.</p></p></figure><div class="NLM_p">The synthesis of <b>19</b> began with a Suzuki coupling to yield isopropene <b>46</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Buchwald–Hartwig coupling between <b>46</b> and <b>28</b> followed by hydrogenation afforded <b>19</b>.</div><figure id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 4,4,5,5-Tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, KOAc, water, CH<sub>3</sub>CN, 100 °C, microwave (45%); (b) <b>28</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, XPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C (65%); (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, rt (56%).</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">By using a structure-based design approach, we identified a novel, noncovalent EGFR inhibitor that exhibits excellent activity against both the activating and resistance mutants of the receptor. In sparing the wild type form of EGFR, a wider therapeutic window can be anticipated relative to first and second generation inhibitors. Without the reliance on a covalent interaction with Cys797, inhibitors of this type should be able to achieve the efficacy of the covalent inhibitors without being subject to the emerging C797S resistance mutation. With strong pathway knock-down in vivo and low predicted human clearance, compound <b>21</b> shows excellent potential for the treatment of EGFR mutant NSCLC. Further in vivo evaluation of compound <b>21</b> will be disclosed in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Synthesis</h3><div class="NLM_p last"><i>General Methods.</i><sup>1</sup>H NMR spectra were recorded at ambient temperature using either a Varian Unity Inova (400 MHz) spectrometer with a triple resonance 5 mm probe, an Avance III (300 MHz) spectrometer, or a Bruker Ultrashield (400 or 500 MHz) spectrometer. Chemical shifts are expressed in ppm relative to tetramethylsilane. The following abbreviations have been used: br = broad signal, s = singlet, d = doublet, dd = double doublet, t = triplet, q = quartet, m = multiplet. Microwave experiments were carried out using a CEM Discover, Smith synthesizer, or a Biotage Initiator 60, which uses a single-mode resonator and dynamic field tuning, both of which give reproducibility and control. Temperatures from 40 to 250 °C can be achieved, and pressures of up to 30 bar can be reached. HPLC/UPLC–mass spectrometry experiments to determine retention times and associated mass ions were performed using various methods which are fully described in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf" class="ext-link">Supporting Information</a>. All final compounds were assessed for purity by UPLC and found to have ≥95% purity. Diastereomeric and enantiomeric purity of final compounds was assessed by UPLC and SFC, respectively, and found to have purity of >95% de and >95% ee. Experimental procedures for selected inhibitors are described below. Experimental procedures for all inhibitors are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf" class="ext-link">Supporting Information</a>. Compounds <b>1</b>–<b>5</b> were prepared as previously described.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a></div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> <i>N</i>-(2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)-1-isopropyl-2-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-amine(<b>7</b>)</h3><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 1-(Cyclopropylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (<b>26</b>)</h4><div class="NLM_p last">To a solution of 4-pyrazoleboronic acid pinacol ester (1.02 g, 5.26 mmol) in DMF (15 mL) were added sodium hydride (60%, 0.32 g, 8 mmol) and cyclopropylsulfonyl chloride (0.8 g, 5.78 mmol). The reaction was stirred at room temperature for 5 h. The mixture was then diluted with brine and extracted with EtOAc (3×). The combined extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by flash chromatography (0–100% EtOAc in heptanes) to give the title compound (0.8 g, 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.29 (s, 1H), 8.01 (s, 1H), 2.77 (m, 1H), 1.48 (m, 2H), 1.33 (s, 12H), 1.16 (m, 2H).</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>N</i>-(2-Chloropyrimidin-4-yl)-1-isopropyl-2-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-amine (<b>23</b>)</h4><div class="NLM_p last">Into a 250 mL three-necked round-bottom flask purged and maintained with nitrogen was added a solution of 6-bromo-1-isopropyl-2-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (3.50 g, 13.0 mmol) in 1,4-dioxane (70.0 mL), 2-chloropyrimidin-4-amine (1.70 g, 13.1 mmol), XantPhos (1.70 g, 2.94 mmol), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (1.70 g, 1.64 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (11.0 g, 33.7 mmol). The resulting mixture was stirred at 100 °C for 4 h. The mixture was cooled to room temperature, the solids were removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography (DCM/MeOH, 50:1) to afford the title compound (1.10 g, 26.1%) as a yellow solid. LCMS (ESI): [M + H]<sup>+</sup> = 303. <sup>1</sup>H NMR (300 Hz, DMSO-<i>d</i><sub>6</sub>): δ 10.55 (s, 1H), 8.57 (s, 1H), 8.26 (d, <i>J</i> = 5.7 Hz, 1H), 8.13 (s, 1H), 7.48 (s, 1H), 4.72–4.68 (m, 1H), 2.58 (s, 3H), 1.57 (d, <i>J</i> = 6.9, 6H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> <i>N</i>-(2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)-1-isopropyl-2-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-amine (<b>7</b>)</h4><div class="NLM_p last">To a reaction vial were added <i>N</i>-cyclopropylsulfonyl-4-pyrazoleboronic acid pinacol ester (0.56 g, 1.8 mmol), <i>N</i>-(2-chloropyrimidin-4-yl)-1-isopropyl-2-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-6-amine (0.56 mg, 1.8 mmol), Pd(Amphos)<sub>2</sub>Cl<sub>2</sub> (65 mg, 0.092 mmol), a 2 M aqueous solution of Na<sub>2</sub>CO<sub>3</sub> (1.4 mL, 2.8 mmol), and acetonitrile (2.5 mL). The mixture was degassed by nitrogen bubbling for 20 min. The reaction vial was sealed and stirred at 100 °C in an oil bath for 3 h. The reaction mixture was cooled to room temperature, filtered, and concentrated. The crude product was purified by reverse phase HPLC to give the title compound (41 mg, 5%). LCMS (ESI): [M + H]<sup>+</sup> 439.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.66 (s, 1H), 8.56 (d, <i>J</i> = 0.8 Hz, 1H), 8.47 (d, <i>J</i> = 0.5 Hz, 1H), 8.39 (m, 2H), 7.24 (s, 1H), 4.78 (m, 1H), 2.58 (s, 3H), 1.63 (d, <i>J</i> = 6.9 Hz, 6H), 1.38–1.21 (m, 4H).</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 6-((2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carboxamide (<b>9</b>)</h3><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 6-Bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine</h4><div class="NLM_p last">To a solution of 6-bromo-5-azaindole (1.0 g, 4.9 mmol) in DMF (8 mL) was added 60% sodium hydride (0.23 g, 5.8 mmol) at 0 °C. The mixture was stirred 0 °C for 5 min prior to the addition of 2-bromopropane (0.7 mL, 7 mmol). The reaction was stirred at room temperature for 2 h. The reaction was then quenched by pouring onto a saturated aqueous solution of NH<sub>4</sub>Cl. The product was extracted with EtOAc (3×). The combined extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel flash chromatography (0–100% EtOAc in heptane) to give the title compound (1.5 g, quant). LCMS (ESI): [M + H]<sup>+</sup> = 239.2.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 6-Bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carbaldehyde</h4><div class="NLM_p last">To cooled (0 °C) DMF (40 mL) was added POCl<sub>3</sub> (3.0 mL, 31 mmol). The reaction was stirred at 0 °C for 20 min. A solution of 6-bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine (4.9 mmol) in DMF (1 mL) was added dropwise at room temperature. The reaction was stirred at 70 °C for 2 h. The mixture was then slowly neutralized by pouring onto a saturated aqueous NaHCO<sub>3</sub> solution. The product was extracted with EtOAc (3×). The combined organic extracts were washed with saturated aqueous NaHCO<sub>3</sub> and brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel flash chromatography (0–100% EtOAc in heptane) to give the title compound (1.34 g, 80%). LCMS (ESI): [M + H]<sup>+</sup> = 267.3.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 6-Bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carboxamide (<b>30</b>)</h4><div class="NLM_p">To a solution of 6-bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carbaldehyde (1.3 g, 4.9 mmol) in <i>t</i>-BuOH (10 mL) was added 2-methyl-2-butene (2 M in THF, 4.1 mL, 49 mmol). A solution of sodium chlorite (1.1 g, 9.7 mmol) and monosodium phosphate (5.8 g, 49 mmol) in water (15 mL) was then added. The reaction was stirred at room temperature for 18 h. The mixture was then diluted with brine and extracted with EtOAc (3×). The combined extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated to give the title compound (1.3 g, 94%). The crude material was used without further purification.</div><div class="NLM_p last">To a solution of the crude 6-bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carboxylic acid (1.25 g, 4.4 mmol) in DMF (10 mL) were added DIPEA (1.2 mL, 6.6 mmol) and HBTU (2.64 g, 6.62 mmol). The mixture was stirred at room temperature for 15 min before the addition of ammonium hydroxide (10 mL). The resulting mixture was stirred vigorously for 1 h. The mixture was then diluted with brine and extracted with EtOAc (3×). The combined extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude material was purified by silica gel flash chromatography (0–10% MeOH in DCM) to give the title compound (0.72 g, 58%). LCMS (ESI): [M + H]<sup>+</sup> = 282.3.</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 6-((2-Chloropyrimidin-4-yl)amino)-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last">To a pressure reaction vessel were added 6-bromo-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carboxamide (0.15 g, 0.53 mmol), 4-amino-2-chloropyrimidine (70 mg, 0.53 mmol), Xantphos (32 mg, 0.053 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (25 mg, 0.027 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.35 g, 1.1 mmol), and 1,4-dioxane (2 mL). The mixture was degassed by nitrogen bubbling for 20 min. The reaction vessel was then sealed and stirred at 120 °C for 6 h. The reaction was then filtered and concentrated. The crude product was purified by silica gel flash chromatography (0–10% MeOH in DCM) to give the title compound (0.70 g, 40%). LCMS (ESI): [M + H]<sup>+</sup> = 331.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 6-((2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carboxamide (<b>9</b>)</h4><div class="NLM_p last">To a glass vial were added 1-(cyclopropylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (95 mg, 0.30 mmol), 6-((2-chloropyrimidin-4-yl)amino)-1-isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-3-carboxamide (50 mg, 0.15 mmol), Pd(Amphos)<sub>2</sub>Cl<sub>2</sub> (5 mg, 0.008 mmol), a 2 M aqueous solution of Na<sub>2</sub>CO<sub>3</sub> (0.11 mL, 0.23 mmol), and acetonitrile (2.5 mL). The mixture was degassed by nitrogen bubbling for 20 min. The reaction vial was sealed and stirred at 100 °C in an oil bath for 1 h. The reaction mixture was cooled to room temperature, filtered, and concentrated. The crude product was purified by reverse phase HPLC and lyophilized to give the title compound (20 mg, 30%). LCMS (ESI): [M + H]<sup>+</sup> = 467.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.27 (s, 1H), 9.08 (t, <i>J</i> = 2.4 Hz, 1H), 8.70 (d, <i>J</i> = 0.5 Hz, 1H), 8.50 (s, 1H), 8.47 (d, <i>J</i> = 0.5 Hz, 1H), 8.37 (d, <i>J</i> = 5.9 Hz, 1H), 8.23 (s, 1H), 7.49 (s, 1H), 7.11 (s, 1H), 6.97 (d, <i>J</i> = 8.7 Hz, 1H), 6.63 (d, <i>J</i> = 8.8 Hz, 1H), 4.80 (m, 1H), 1.56 (d, <i>J</i> = 6.7 Hz, 6H), 1.40–1.31 (m, 2H), 1.30–1.23 (m, 2H).</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)-1-isopropyl-3-morpholino-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-amine (<b>15</b>)</h3><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-(6-Bromo-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)morpholine</h4><div class="NLM_p last">A mixture of 6-bromo-3-iodo-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (1 g, 2.73 mmol), CuI (103.8 mg, 0.550 mmol), <span class="smallcaps smallerCapital">l</span>-proline (94.3 mg, 0.820 mmol), K<sub>2</sub>CO<sub>3</sub> (943 mg, 6.82 mmol), and morpholine (713 mg, 8.19 mmol) in DMF (10 mL) was irradiated with microwave radiation for 2 h at 100 °C under an atmosphere of nitrogen. The resulting solution was diluted with water and extracted with ethyl acetate. The organic extract was washed with brine and then dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel flash chromatography (10% EtOAc in petroleum ether) to afford the title compound (140 mg, 16%) as a white solid. LCMS (ESI): [M + H]<sup>+</sup> = 325/327.</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-amine (<b>28</b>)</h4><div class="NLM_p last">To a reaction vessel was added Pd(Amphos)<sub>2</sub>Cl<sub>2</sub> (370 mg, 0.50 mmol), 1-(cyclopropylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1.5 g, 4.3 mmol), 2-bromopyrimidin-4-amine (880 mg, 5.0 mmol), a 2 M aqueous solution of Na<sub>2</sub>CO<sub>3</sub> in water (5.0 mL, 10 mmol), and acetonitrile (8.4 mL, 160 mmol). The reaction vessel was sealed and heated to 100 °C in an oil bath. After 2 h, the reaction was cooled to room temperature, diluted with saturated aqueous NaHCO<sub>3</sub>, and extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was then purified via silica gel flash chromatography (0%–10% MeOH in DCM) to give the title compound (1129 g, 85%) as a yellow solid. LCMS (ESI) [M + H]<sup>+</sup> = 266.1; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.44 (s, 1H), 8.27 (d, <i>J</i> = 5.1 Hz, 1H), 7.06 (d, <i>J</i> = 5.1 Hz, 1H), 6.63 (s, 2H), 3.22 (m, 1H), 1.38–1.29 (m, 2H), 1.28–1.19 (m, 2H).</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)-1-isopropyl-3-morpholino-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-6-amine (<b>15</b>)</h4><div class="NLM_p last">To a reaction vessel were added 4-[6-bromo-1-(propan-2-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl]morpholine (100 mg, 0.310 mmol), Xantphos (35 mg, 0.060 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (28.0 mg, 0.030 mmol), Cs<sub>2</sub>CO<sub>3</sub> (251 mg, 0.770 mmol), 2-[1-(cyclopropanesulfonyl)-1<i>H</i>-pyrazol-4-yl]pyrimidin-4-amine (97.8 mg, 0.370 mmol), and 1,4-dioxane (5 mL). The mixture was degassed by nitrogen bubbling for 5 min. The resulting solution was stirred for 3 h at 90 °C and then cooled to room temperature. The reaction mixture was concentrated in vacuo. The crude product was purified via silica gel flash chromatography (0%–4% MeOH in DCM) to give the title compound (25.6 mg, 16%) as an off-white solid. LCMS (ESI): [M + H]<sup>+</sup> 510.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.37 (s, 1H), 8.91 (s, 1H), 8.70 (s, 1H), 8.47 (s, 1H), 8.42–8.40 (d, <i>J</i> = 6.0 Hz, 1H), 8.34 (s, 1H), 7.12–7.10 (d, <i>J</i> = 6.0 Hz, 1H), 4.77–4.72 (m, 1H), 3.81–3.78 (m, 4H), 3.42–3.39 (m, 4H), 3.31–3.26 (m, 1H), 1.48–1.46 (d, <i>J</i> = 6.6 Hz, 6H), 1.35–1.32 (m, 2H), 1.29–1.23 (m, 2H).</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 2-(1-(6-((2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>18</b>)</h3><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-Chloro-3-iodo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine</h4><div class="NLM_p last">To a solution of 6-chloro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (5.2 g, 34 mmol) in DMF (75 mL) were added K<sub>2</sub>CO<sub>3</sub> (5.7 g, 41 mmol) and iodine (4.3 g, 41 mmol). The reaction was stirred at room temperature. After 4 h, additional iodine (4.3 g, 17 mmol) and K<sub>2</sub>CO<sub>3</sub> (2.3 g, 17 mmol) were added. After 16 h of stirring at room temperature, the reaction was diluted with saturated aqueous NaHCO<sub>3</sub> and extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified via silica gel flash chromatography (0%–100% EtOAc in heptane) to give the title compound (7.5 g, 79%). LCMS (ESI) [M + H]<sup>+</sup> = 280. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.02 (br, 1H), 8.63 (br, 1H), 7.69 (s, 1H).</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 6-Chloro-3-iodo-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine</h4><div class="NLM_p last">To a solution of 6-chloro-3-iodo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (1.5 g, 5.4 mmol) in DMF (8 mL) was added sodium hydride (60 wt % dispersion in mineral oil, 260 mg, 6.4 mmol) at 0 °C. The reaction was stirred at 0 °C for 5 min before adding 2-bromopropane (0.76 mg, 8.1 mmol). The reaction was warmed to room temperature and stirred for 2 h, after which the reaction was diluted with saturated aqueous NH<sub>4</sub>Cl, and extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified via silica gel flash chromatography (0%–100% EtOAc in heptanes) to provide the title compound (1390 mg, 81%) as a pale yellow solid. LCMS (ESI) [M + H]<sup>+</sup> = 322.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (s, 1H), 7.34 (s, 1H), 4.78–4.71 (m, 1H), 1.60 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-(1-(6-Chloro-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl)propan-2-ol</h4><div class="NLM_p last">To a reaction vessel were added 6-chloro-3-iodo-1-(propan-2-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (300 mg, 0.930 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (85.4 mg, 0.090 mmol), XantPhos (108 mg, 0.190 mmol), Cs<sub>2</sub>CO<sub>3</sub> (608 mg, 1.87 mmol), 2-(azetidin-3-yl)propan-2-ol (107 mg, 0.930 mmol), and 1,4-dioxane (8 mL). The mixture was stirred for 6 h at 100 °C. The reaction mixture was cooled to room temperature, and the solids were removed by filtration. The filtrate was concentrated in vacuo. The crude product was purified via silica gel flash chromatography (0%–50% EtOAc in petroleum ether) to provide the title compound (130 mg, 45%) as a white solid. LCMS (ESI): [M + H]<sup>+</sup> = 309.</div></div><div id="sec5_1_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-(1-(6-((2-(1-(Cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>18</b>)</h4><div class="NLM_p last">In a reaction vessel were placed 2-[1-[6-chloro-1-(propan-2-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl]azetidin-3-yl]propan-2-ol (120 mg, 0.390 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (35.6 mg, 0.04 mmol), Xantphos (45.0 mg, 0.08 mmol), Cs<sub>2</sub>CO<sub>3</sub> (253 mg, 0.780 mmol), 2-[1-(cyclopropanesulfonyl)-1<i>H</i>-pyrazol-4-yl]pyrimidin-4-amine (103 mg, 0.390 mmol), and 1,4-dioxane (8 mL). The mixture was heated with microwave radiation for 45 min at 160 °C. The reaction was filtered and concentrated in vacuo. The crude product was purified via silica gel flash chromatography (0%–10% methanol in DCM) to provide the title compound (26.8 mg, 13%) as a light yellow solid. LCMS (ESI): [M + H]<sup>+</sup> = 538.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.32 (s, 1H), 8.69 (s, 1H), 8.61 (s, 1H), 8.47 (s, 1H), 8.40 (d, <i>J</i> = 5.6 Hz,1H), 8.27 (s, 1H), 7.13 (d, <i>J</i> = 5.6 Hz, 1H), 4.71–4.67 (m, 1H), 4.44 (s, 1H), 4.07–4.01 (m, 4H), 3.29–3.27 (m, 1H), 2.84–2.81 (m, 1H), 1.46 (d, <i>J</i> = 6.8 Hz, 6H), 1.34 (m, 2H), 1.30–1.23 (m, 2H), 1.08 (s, 6H).</div></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>R</i>)-2-(1-(1-(<i>sec</i>-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>20</b>) and (<i>S</i>)-2-(1-(1-(<i>sec</i>-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>21</b>)</h3><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (±)-1-(<i>sec</i>-Butyl)-6-chloro-3-iodo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine</h4><div class="NLM_p last">To a solution of 6-chloro-3-iodo-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (3.5 g, 13 mmol) in DMF (25 mL) was added sodium hydride (60 wt % dispersion in mineral oil, 0.6 g, 15 mmol). The reaction mixture was stirred at room temperature for 10 min prior to the addition of 2-bromobutane (2.7 mL, 25 mmol). The reaction was stirred at room temperature for 5 h, diluted with brine, and extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified via silica gel flash chromatography (0%–100% EtOAc in heptane) to give the title compound (3.6 g, 86%). LCMS (ESI): [M + H]<sup>+</sup> = 336. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (s, 1H), 7.31 (s, 1H), 4.54–4.35 (m, 1H), 2.15–1.99 (m, 1H), 1.98–1.81 (m, 1H), 1.61–1.49 (m, 3H), 0.79 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (±)-2-[1-(6-Chloro-1-<i>sec</i>-butylpyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl]propan-2-ol</h4><div class="NLM_p last">To a reaction vessel were added 6-chloro-3-iodo-1-isopropyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridine (1.0 g, 1.4 mmol), 2-(azetidin-3-yl)propan-2-ol (0.41g, 3.6 mmol), K<sub>2</sub>CO<sub>3</sub> (1.4 g, 10 mmol), <span class="smallcaps smallerCapital">l</span>-proline (0.17 g, 1.5 mmol), copper(I) iodide (0.28 g, 1.5 mmol), and DMF (8 mL). The reaction was degassed by nitrogen bubbling for 20 min. The reaction vessel was sealed and stirred at 90 °C. After 3.5 h, the reaction was cooled to room temperature, filtered, and extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified via silica gel flash chromatography (0%–100% EtOAc in heptane) to give the title compound (0.45 g, 47%). LCMS (ESI): [M + H]<sup>+</sup> = 323.3.</div></div><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>R</i>)-2-(1-(1-(<i>sec</i>-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>20</b>) and (<i>S</i>)-2-(1-(1-(<i>sec</i>-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-yl)amino)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>21</b>)</h4><div class="NLM_p">To a reaction vessel were added (±)-2-[1-(6-chloro-1-<i>sec</i>-butylpyrazolo[4,3-<i>c</i>]pyridin-3-yl)azetidin-3-yl]propan-2-ol (0.25 g, 0.68 mmol), 2-(1-(cyclopropylsulfonyl)-1<i>H</i>-pyrazol-4-yl)pyrimidin-4-amine (0.18 g, 0.68 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.44 g, 1.4 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (66 mg, 0.14 mmol), tris(dibenzylideneacetone)dipalladium(0) (31 mg, 0.034 mmol), and 1,4-dioxane (3 mL). The reaction was degassed by nitrogen bubbling for 20 min and heated at 100 °C for 3 h. The reaction mixture was cooled to room temperature, filtered, and concentrated in vacuo. The products were purified and the enantiomers were separated by chiral supercritical fluid chromatography to give the title compounds (absolute stereochemistry assigned by X-ray structure of <b>21</b> complexed with EGFR TMLR; see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p"><i>(R)-2-(1-(1-(sec-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>20</b>)</i>. Yield: 43.4 mg, 12%. LCMS [M + H]<sup>+</sup> = 552.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 8.69 (s, 1H), 8.62 (d, <i>J</i> = 1.0 Hz, 1H), 8.48 (s, 1H), 8.40 (d, <i>J</i> = 5.9 Hz, 1H), 8.26 (s, 1H), 7.14 (d, <i>J</i> = 5.9 Hz, 1H), 4.46 (s, 1H), 4.35–4.44 (m, 1H), 4.01–4.08 (m, 4H), 3.26–3.32 (m, 1H), 2.79–2.86 (m, 1H), 1.87–1.99 (m, 1H), 1.73–1.85 (m, 1H), 1.45 (d, <i>J</i> = 6.6 Hz, 3H), 1.23–1.36 (m, 4H), 1.09 (s, 6H), 0.73 (t, <i>J</i> = 7.3 Hz, 3H).</div><div class="NLM_p last"><i>(S)-2-(1-(1-(sec-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)propan-2-ol (<b>21</b>).</i> Yield: 40.1 mg, 11%. [M + H]<sup>+</sup> = 552.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 8.69 (s, 1H), 8.62 (d, <i>J</i> = 1.0 Hz, 1H), 8.47 (s, 1H), 8.41 (d, <i>J</i> = 5.9 Hz, 1H), 8.26 (s, 1H), 7.12 (d, <i>J</i> = 5.9 Hz, 1H), 4.46 (s, 1H), 4.37–4.42 (m, 1H), 4.01–4.8 (m, 4H), 3.26–3.32 (m, 1H), 2.79–2.87 (m, 1H), 1.88–1.99 (m, 1H), 1.76–1.83 (m, 1H), 1.45 (d, <i>J</i> = 6.6 Hz, 3H), 1.24–1.37 (m, 4H), 1.08 (s, 6H), 0.72 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.96, 158.34, 156.23, 153.02, 149.46, 145.18, 144.28, 143.45, 131.73, 126.07, 109.53, 107.20, 90.88, 68.30, 55.55, 54.06, 42.24, 31.24, 29.14, 27.11, 20.39, 11.53, 7.29.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Enzymatic Assays</h3><div class="NLM_p last">Enzymatic assays were carried out as previously described.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> All enzymatic data reported are the geometric mean values of at least two independent experiments.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Cellular Assays</h3><div class="NLM_p last">All pEGFR MSD and H1975 proliferation assays were carried out as previously described.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> In Vitro Microsome and Hepatocyte Metabolic Stability Assays</h3><div class="NLM_p last">Experiments were carried out as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Values shown are for predicted hepatic clearance using intrinsic clearance and a conversion factor for liver blood flow to predict hepatic clearance:<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Cl<sub>hep</sub>= (<i>Q</i> × Cl<sub>int</sub>)/(<i>Q</i> + Cl<sub>int</sub>) where Cl<sub>hep</sub> is the predicted hepatic clearance, <i>Q</i> is the liver blood flow, and Cl<sub>int</sub> is the intrinsic clearance. Liver blood flow values in mL min<sup>–1</sup> kg<sup>–1</sup> are the following: rat, 55.2; dog, 30.9; human, 20.7; mouse, 90.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> X-ray Crystallography</h3><div class="NLM_p last">Crystallographic methods and the production and use of the TMLR proteins were as previously described.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00995">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00995" class="ext-link">10.1021/acs.jmedchem.6b00995</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Kinase selectivity profiling data for <b>21</b>; X-ray structure of <b>21</b> complexed with EGFR TMLR double mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCZ">5HCZ</a>); crystallographic data collection and refinement statistics; molecular modeling methods; in vivo xenograft pharmacodynamics studies materials and methods; experimental details for the preparation of all compounds; NMR data for key compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf">jm6b00995_si_001.pdf (874.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_002.csv">jm6b00995_si_002.csv (2.62 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: TMLR/<b>3</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>; TMLR/<b>7</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCX">5HCX</a>; TMLR/<b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCY">5HCY</a>; TMLR/<b>21</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCZ">5HCZ</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00995" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan K. Chan</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6e0d060f00400c1c170f002e090b000b400d0103"><span class="__cf_email__" data-cfemail="b0d3d8d1de9ed2c2c9d1def0d7d5ded59ed3dfdd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily J. Hanan</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Krista K. Bowman</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marian C. Bryan</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Burdick</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily Chan</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuan Chen</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saundra Clausen</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Trisha Dela Vega</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennafer Dotson</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Eigenbrot</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard L. Elliott</span> - <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Heald</span> - <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip S. Jackson</span> - <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jamie D. Knight</span> - <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hank La</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Lainchbury</span> - <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiva Malek</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans E. Purkey</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabriele Schaefer</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Schmidt</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eileen M. Seward</span> - <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Sideris</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lily Shao</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shumei Wang</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siew Kuen Yeap</span> - <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ivana Yen</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Yu</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy P. Heffron</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Structural Biology, §Drug Metabolism and
Pharmacokinetics, ∥Biochemical and Cellular Pharmacology, ⊥Molecular Oncology, #Research Oncology, and ∇Protein Expression, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Charles River
Laboratories, 7/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3746-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Crystallographic Consulting LLC for diffraction data collection services and Mark Ultsch and Christine Huang for assistance with some crystals. The Advanced Light Source (ALS) is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract DE-AC0205CH11231. The Berkeley Center for Structural Biology is supported in part by the National Institutes of Health, National Institute of General Medical Sciences, and the Howard Hughes Medical Institute. Use of the Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the National Institutes of Health, National Institute of General Medical Sciences (including Grant P41GM103393). The authors thank the medicinal chemistry, analytical and purification groups at Genentech, Argenta, and Pharmaron for their synthetic, analytical, and purification support. The authors thank Savita Ubhayakar, Xiaorong Liang, Ning Liu, Quynh Ho, and Kirsten Messick for in vitro and in vivo PK and bioanalytical support. The authors also thank Professor François Diederich for the stimulating discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> Abbreviations Used</h2><tr><td class="NLM_term">A</td><td class="NLM_def"><p class="first last">apical</p></td></tr><tr><td class="NLM_term">Amphos</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl-(4-dimethylaminophenyl)phosphine</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, elimination</p></td></tr><tr><td class="NLM_term">B</td><td class="NLM_def"><p class="first last">basolateral</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">twice a day</p></td></tr><tr><td class="NLM_term">BrettPhos</td><td class="NLM_def"><p class="first last">2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl</p></td></tr><tr><td class="NLM_term">Cl<sub>hep</sub></td><td class="NLM_def"><p class="first last">predicted hepatic clearance</p></td></tr><tr><td class="NLM_term">del<sub>746–750</sub></td><td class="NLM_def"><p class="first last">epidermal growth factor receptor (del<sub>746–750</sub>)</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">erlotinib resistant</p></td></tr><tr><td class="NLM_term"><i>F</i><sub>u</sub></td><td class="NLM_def"><p class="first last">unbound fraction</p></td></tr><tr><td class="NLM_term">H</td><td class="NLM_def"><p class="first last">human</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(1<i>H</i>-benzotriazol-1-yl)uronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">Hep</td><td class="NLM_def"><p class="first last">hepatocyte</p></td></tr><tr><td class="NLM_term">K. sol.</td><td class="NLM_def"><p class="first last">kinetic solubility</p></td></tr><tr><td class="NLM_term">L858R</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor (L858R)</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsome</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">mouse</p></td></tr><tr><td class="NLM_term">MCT</td><td class="NLM_def"><p class="first last">medium chain triglyeride</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)dipalladium(0)</p></td></tr><tr><td class="NLM_term">pEGFR</td><td class="NLM_def"><p class="first last">phosphorylated epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">quant</td><td class="NLM_def"><p class="first last">quantitative</p></td></tr><tr><td class="NLM_term">R</td><td class="NLM_def"><p class="first last">rat</p></td></tr><tr><td class="NLM_term">TMLR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor (T790M/L858R)</p></td></tr><tr><td class="NLM_term">TMdel</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor (T790M/del<sub>746–750</sub>)</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">wtEGFR</td><td class="NLM_def"><p class="first last">wild type epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">XPhos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr><tr><td class="NLM_term">XantPhos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Inhibition of EGFR signaling: all mutations are not created equal</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e377</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1371%2Fjournal.pmed.0020377" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e377&author=A.+F.+Gazdarauthor=J.+D.+Minna&title=Inhibition+of+EGFR+signaling%3A+all+mutations+are+not+created+equal&doi=10.1371%2Fjournal.pmed.0020377"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020377%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520EGFR%2520signaling%253A%2520all%2520mutations%2520are%2520not%2520created%2520equal%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De377%26doi%3D10.1371%2Fjournal.pmed.0020377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhSY498LSFyKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span><span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0lhSY498LSFyKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7241</span><span class="NLM_x">–</span> <span class="NLM_lpage">7244</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F0008-5472.CAN-04-1905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7241-7244&author=S.+Tracyauthor=T.+Mukoharaauthor=M.+Hansenauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=P.+A.+Janne&title=Gefitinib+induces+apoptosis+in+the+EGFRL858R+non-small-cell+lung+cancer+cell+line+H3255&doi=10.1158%2F0008-5472.CAN-04-1905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1905%26sid%3Dliteratum%253Aachs%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DGefitinib%2520induces%2520apoptosis%2520in%2520the%2520EGFRL858R%2520non-small-cell%2520lung%2520cancer%2520cell%2520line%2520H3255%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7241%26epage%3D7244%26doi%3D10.1158%2F0008-5472.CAN-04-1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Oncogene addiction: setting the stage for molecularly targeted cancer therapy</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3214</span><span class="NLM_x">–</span> <span class="NLM_lpage">3231</span><span class="refDoi"> DOI: 10.1101/gad.1609907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1101%2Fgad.1609907" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=3214-3231&author=S.+V.+Sharmaauthor=J.+Settleman&title=Oncogene+addiction%3A+setting+the+stage+for+molecularly+targeted+cancer+therapy&doi=10.1101%2Fgad.1609907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1101%2Fgad.1609907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1609907%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DOncogene%2520addiction%253A%2520setting%2520the%2520stage%2520for%2520molecularly%2520targeted%2520cancer%2520therapy%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D3214%26epage%3D3231%26doi%3D10.1101%2Fgad.1609907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Jackman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffredi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5267</span><span class="NLM_x">–</span> <span class="NLM_lpage">5273</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-09-0888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=19671843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5267-5273&author=D.+M.+Jackmanauthor=V.+A.+Millerauthor=L.+A.+Cioffrediauthor=B.+Y.+Yeapauthor=P.+A.+Janneauthor=G.+J.+Rielyauthor=M.+G.+Ruizauthor=G.+Giacconeauthor=L.+V.+Sequistauthor=B.+E.+Johnson&title=Impact+of+epidermal+growth+factor+receptor+and+KRAS+mutations+on+clinical+outcomes+in+previously+untreated+non-small+cell+lung+cancer+patients%3A+results+of+an+online+tumor+registry+of+clinical+trials&doi=10.1158%2F1078-0432.CCR-09-0888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online Tumor registry of clinical trials</span></div><div class="casAuthors">Jackman, David M.; Miller, Vincent A.; Cioffredi, Leigh-Anne; Yeap, Beow Y.; Jaenne, Pasi A.; Riely, Gregory J.; Ruiz, Marielle Gallegos; Giaccone, Giuseppe; Sequist, Lecia V.; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5267-5273</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated.  This study combines patient data from five trials in predominantly Western populations to assess the impact of EGFR and KRAS mutations on first-line therapy with an EGFR-tyrosine kinase inhibitor (TKI) and compare clin. vs. mol. predictors of sensitivity.  Chemotherapy-naive patients with advanced non-small cell lung cancer and known EGFR mutation status treated with erlotinib or gefitinib monotherapy as part of a clin. trial were eligible for inclusion.  Patients received daily erlotinib (150 mg) or gefitinib (250 mg) until disease progression or unacceptable toxicity.  Data were collected in a password-protected web database.  Clin. outcomes were analyzed to look for differences based on EGFR and KRAS genotypes, as well as clin. characteristics.  Patients (223) from five clin. trials were included.  Sensitizing EGFR mutations were assocd. with a 67% response rate, time to progression (TTP) of 11.8 mo, and overall survival of 23.9 mo.  Exon 19 deletions were assocd. with longer median TTP and overall survival compared with L858R mutations.  Wild-type EGFR was assocd. with poorer outcomes (response rate, 3%; TTP, 3.2 mo) irresp. of KRAS status.  No difference in outcome was seen between patients harboring KRAS transition vs. transversion mutations.  EGFR genotype was more effective than clin. characteristics at selecting appropriate patients for consideration of first-line therapy with an EGFR-TKI.  EGFR mutation status is assocd. with sensitivity to treatment with an EGFR-TKI in patients with advanced non-small cell lung cancer.  Patients harboring sensitizing EGFR mutations should be considered for first-line erlotinib or gefitinib. (Clin Cancer Res 2009;15(16):5267-73).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUmIDiCjeVvrVg90H21EOLACvtfcHk0lj16AWXpbi0Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D&md5=2d9669c6e4c396d632424c1c0190868c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0888%26sid%3Dliteratum%253Aachs%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCioffredi%26aufirst%3DL.%2BA.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DRuiz%26aufirst%3DM.%2BG.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DImpact%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520KRAS%2520mutations%2520on%2520clinical%2520outcomes%2520in%2520previously%2520untreated%2520non-small%2520cell%2520lung%2520cancer%2520patients%253A%2520results%2520of%2520an%2520online%2520tumor%2520registry%2520of%2520clinical%2520trials%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5267%26epage%3D5273%26doi%3D10.1158%2F1078-0432.CCR-09-0888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Larriba, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Screening for epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span><span class="refDoi"> DOI: 10.1056/NEJMoa0904554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa0904554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=19692684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=958-967&author=R.+Rosellauthor=T.+Moranauthor=C.+Queraltauthor=R.+Portaauthor=F.+Cardenalauthor=C.+Campsauthor=M.+Majemauthor=G.+Lopez-Vivancoauthor=D.+Islaauthor=M.+Provencioauthor=A.+Insaauthor=B.+Massutiauthor=J.+L.+Gonzalez-Larribaauthor=L.+Paz-Aresauthor=I.+Boverauthor=R.+Garcia-Campeloauthor=M.+A.+Morenoauthor=S.+Catotauthor=C.+Rolfoauthor=N.+Reguartauthor=R.+Palmeroauthor=J.+M.+Sanchezauthor=R.+Bastusauthor=C.+Mayoauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=J.+J.+Sanchezauthor=M.+Taron&title=Screening+for+epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1056%2FNEJMoa0904554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Gonzalez-Larriba, Jose Luis; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Moreno, Miguel Angel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Sanchez, Jose Miguel; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Molina, Miguel Angel; Sanchez, Jose Javier; Taron, Miquel; Cuello, M.; Pallares, C.; Lianes, P.; Remon, J.; Ibeas, R.; Martinez del Prado, P.; Angeles Sala, M.; Santander-Lobera, C.; Velez de Mendizabal, E.; Vinolas, N.; Terrasa, J.; Valdivia, J.; Diz, P.; Jimenez-Berlana, U.; Velasco-Ortiz de Taranco, A.; Ales Martinez, E.; Sanchez-Escribano, R.; Carrato, A.; Guillen-Ponce, C.; Mesia, C.; Antonio Macias, J.; Lopez-Brea, M.; Oramas, J.; Barneto, I.; Garrido, P.; Mayol, M. J.; Lopez, A.; Artal, A.; Saenz, A.; Hernando, S.; Cobo, M.; Blanco, R.; Bernabe, R.; Guillem, V.; Angel Munoz, M.; Maestu, I.; Salvatierra, A.; De Las Penas, R.; Alfaro, J.; Alberola, V.; Juan, O.; Martin, C.; Puertas, J.; Felip, E.; Gonzalez-Gonzalez, J. F.; Iglesias-Docampo, L.; Dorta, F. J.; Martinez-Aguillo, M.; Salgado, E.; Mesia, R.; Lastra-Aras, E.; Garcia-Munoz, J. P.; Lastra, R.; Alvarez, I.; Roig, J.; Oruezabal, J.; Poveda, A.; Lavernia, J.; Gutierrez, D.; Filipovich, E.; Aguiar, D.; Rodriguez, D.; Buxo, J.; Cardona, A. F.; Bes, P.; Paredes, A.; Tortorella, A. M.; Moreno, J. A.; Martinez-Garcia, J.; Alonso, J. L.; Lopez-Martin, A.; Echarri-Gonzalez, M. J.; Van Kooten, M.; Guerrero, A.; Domine, M.; Diaz, I.; Heras, L.; Garcia, R.; Anton, I.; Jarchum, G.; Bartolucci, R. E.; Lomas, M.; Rubiales, A.; Duque, J. L.; Escriva de Romani, S.; Barbeta, E.; Reina, J. J.; Castro, J.; Belda, C.; Vidal, J. M.; Trigo, J. M.; Vadell, C.; Zarba, J. J.; Esunza, P.; Garau, I.; Lopez-Pousa, A.; De la Gandara, I.; Widakowich, J.; Morales, S.; Martinez, M.; Luis, R.; de la Colina, M.; Calzas, J.; Garcia-Castro, I.; Ruiz, C.; Lopez-Criado, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">958-967</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer.  We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the assocn. between the mutations and the outcome of erlotinib treatment.  From Apr. 2005 through Nov. 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations.  The anal. was performed in a central lab.  Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment.  EGFR mutations were found in 350 of 2105 patients (16.6%).  Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P < 0.001 for all comparisons).  The mutations were deletions in exon 19 (62.2%) and L858R (37.8%).  Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 mo and 27 mo, resp.  The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P < 0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P = 0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P = 0.02).  The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%).  Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvZWnSnU_ScbVg90H21EOLACvtfcHk0lj16AWXpbi0Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M&md5=288ea35bd5201579d8c89ad6d7c4306a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904554%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DCamps%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DGonzalez-Larriba%26aufirst%3DJ.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DCatot%26aufirst%3DS.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DBastus%26aufirst%3DR.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DScreening%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D958%26epage%3D967%26doi%3D10.1056%2FNEJMoa0904554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span><span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lj8Xk3X_2mFkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lj8Xk3X_2mFkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span><span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%22never+smokers%22+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%2522never%2520smokers%2522%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">May 20 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">8027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=8027&issue=May+20+Suppl.&author=P.+A.+Janneauthor=J.+H.+Schellensauthor=J.+A.+Engelmanauthor=S.+G.+Eckhardtauthor=R.+Millhamauthor=L.+J.+Denisauthor=C.+D.+Brittenauthor=S.+G.+Wongauthor=D.+S.+Bossauthor=D.+R.+Camidge&title=Preliminary+activity+and+safety+results+from+a+phase+I+clinical+trial+of+PF-00299804%2C+an+irreversible+pan-HER+inhibitor%2C+in+patients+%28pts%29+with+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520activity%2520and%2520safety%2520results%2520from%2520a%2520phase%2520I%2520clinical%2520trial%2520of%2520PF-00299804%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3DMay%252020%2520Suppl%26spage%3D8027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span><span class="refDoi"> DOI: 10.1200/JCO.2009.27.9414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2009.27.9414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0lgBA6NTIFuudA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083%26doi%3D10.1200%2FJCO.2009.27.9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.1038/nrc2947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer&doi=10.1038%2Fnrc2947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0lgBA6NTIFuudA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774%26doi%3D10.1038%2Fnrc2947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljnDZ02zfUm5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2ea6seHGoOp6rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+Disappointment%3A+Covalent+Inhibitors+to+Overcome+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0ljnDZ02zfUm5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520Disappointment%253A%2520Covalent%2520Inhibitors%2520to%2520Overcome%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lh9uTBxmD9kxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuboi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span> </span><span class="NLM_article-title">Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5769</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-06-0714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17020982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5764-5769&author=T.+Kosakaauthor=Y.+Yatabeauthor=H.+Endohauthor=K.+Yoshidaauthor=T.+Hidaauthor=M.+Tsuboiauthor=H.+Tadaauthor=H.+Kuwanoauthor=T.+Mitsudomi&title=Analysis+of+epidermal+growth+factor+receptor+gene+mutation+in+patients+with+non-small+cell+lung+cancer+and+acquired+resistance+to+gefitinib&doi=10.1158%2F1078-0432.CCR-06-0714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib</span></div><div class="casAuthors">Kosaka, Takayuki; Yatabe, Yasushi; Endoh, Hideki; Yoshida, Kimihide; Hida, Toyoaki; Tsuboi, Masahiro; Tada, Hirohito; Kuwano, Hiroyuki; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5764-5769</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Non-small cell lung cancers carrying activating mutations in the gene for the epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine kinase inhibitors.  However, most patients who initially respond subsequently experience disease progression while still on treatment.  Part of this "acquired resistance" is attributable to a secondary mutation resulting in threonine to methionine at codon 790 (T790M) of EGFR.  Exptl. Design: We sequenced exons 18 to 21 of the EGFR gene to look for secondary mutations in tumors with acquired resistance to gefitinib in 14 patients with adenocarcinomas.  Subcloning or cycleave PCR was used in addn. to normal sequencing to increase the sensitivity of the assay.  We also looked for T790M in pretreatment samples from 52 patients who were treated with gefitinib.  We also looked for secondary KRAS gene mutations because tumors with KRAS mutations are generally resistant to tyrosine kinase inhibitors.  RESULTS: Seven of 14 tumors had a secondary T790M mutation.  There were no other novel secondary mutations.  We detected no T790M mutations in pretreatment specimens from available five tumors among these seven tumors.  Patients with T790M tended to be women, never smokers, and carrying deletion mutations, but the T790M was not assocd. with the duration of gefitinib administration.  None of the tumors had an acquired mutation in the KRAS gene.  CONCLUSIONS: A secondary T790M mutation of EGFR accounted for half the tumors with acquired resistance to gefitinib in Japanese patients.  Other drug-resistant secondary mutations are uncommon in the EGFR gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZou5KHFws9bVg90H21EOLACvtfcHk0lh9uTBxmD9kxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL&md5=331c3e60cb4470484b418ee1b9a80674</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0714%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DTsuboi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DKuwano%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DAnalysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520gene%2520mutation%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5764%26epage%3D5769%26doi%3D10.1158%2F1078-0432.CCR-06-0714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Balak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouerfelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6494</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-06-1570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0lh9uTBxmD9kxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501%26doi%3D10.1158%2F1078-0432.CCR-06-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">Erlotinib activity in biochemical assays: wtEGFR <i>K</i><sub>i</sub> = 0.1 nM, EGFR(del<sub>746–750</sub>) <i>K</i><sub>i</sub> = 0.1 nM, EGFR(T790M/L858R) <i>K</i><sub>i</sub> = 123 nM, EGFR(T790M/del<sub>746–750</sub>) <i>K</i><sub>i</sub> = 95 nM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span><span class="refDoi"> DOI: 10.1073/pnas.0502860102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib&doi=10.1073%2Fpnas.0502860102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0ljLKzq1_5agLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.0502860102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0ljLKzq1_5agLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: the new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1038/nrd2324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17853901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+the+new+wave+of+BCR-ABL+inhibitors&doi=10.1038%2Fnrd2324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Flying under the radar: the new wave of BCR-ABL inhibitors</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia caused by the mutant BCR-ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs.  Quintas-Cardama and colleagues discuss novel BCR-ABL inhibitors that have the potential to overcome such resistance.  The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukemia (CML).  However, most patients with CML receiving imatinib still harbor mol. residual disease and some develop resistance assocd. with ABL kinase domain mutations.  The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clin. trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML.  Various medicinal chem. efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clin. trials, including against T315I mutants.  Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2DBi1E-INLVg90H21EOLACvtfcHk0lg92t9rCzu8qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ&md5=6a8692cd0405f77256df82ae7de21e18</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520the%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848%26doi%3D10.1038%2Fnrd2324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lg92t9rCzu8qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Soria, J.-C.; Sequist, L. V.; Gadgeel, S.; Goldman, J.; Wakelee, H.; Varga, A.; Fidias, P.; Wozniak, A. J.; Neal, J. W.; Doebele, R. C.; Garon, E. B.; Jaw-Tsai, S.; Caunt, L.; Kaur, P.; Rolfe, L.; Allen, A.; Camidge, D. R.</span><span> </span><span class="NLM_article-title">First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)</span>. Presented at the 15th World Conference on Lung Cancer, Sydney, Australia,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.-C.+Soria&author=L.+V.+Sequist&author=S.+Gadgeel&author=J.+Goldman&author=H.+Wakelee&author=A.+Varga&author=P.+Fidias&author=A.+J.+Wozniak&author=J.+W.+Neal&author=R.+C.+Doebele&author=E.+B.+Garon&author=S.+Jaw-Tsai&author=L.+Caunt&author=P.+Kaur&author=L.+Rolfe&author=A.+Allen&author=D.+R.+Camidge&title=First-in-human+evaluation+of+CO-1686%2C+an+irreversible%2C+highly+selective+tyrosine+kinase+inhibitor+of+mutations+of+EGFR+%28activating+and+T790M%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DFirst-in-human%2520evaluation%2520of%2520CO-1686%252C%2520an%2520irreversible%252C%2520highly%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520of%2520mutations%2520of%2520EGFR%2520%2528activating%2520and%2520T790M%2529%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Preliminary results from a phase I study with AZD9291</span>. Presented at the European Cancer Congress,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Ranson&title=Preliminary+results+from+a+phase+I+study+with+AZD9291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%2520I%2520study%2520with%2520AZD9291%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljFidxa-t5sPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1479</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Ojsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+T.+T.+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+Vitro+and+In+Vivo+Characterization+of+Irreversible+Mutant-Selective+EGFR+Inhibitors+That+Are+Wild-Type+Sparing&doi=10.1158%2F1535-7163.MCT-13-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing</span></div><div class="casAuthors">Sjin, Robert Tjin Tham; Lee, Kwangho; Walter, Annette O.; Dubrovskiy, Aleksandr; Sheets, Michael; Martin, Thia St.; Labenski, Matthew T.; Zhu, Zhendong; Tester, Richland; Karp, Russell; Medikonda, Aravind; Chaturvedi, Prasoon; Ren, Yixuan; Haringsma, Henry; Etter, Jeff; Raponi, Mitch; Simmons, Andrew D.; Harding, Thomas C.; Niu, Deqiang; Nacht, Mariana; Westlin, William F.; Petter, Russell C.; Allen, Andrew; Singh, Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-1479</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approx. 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFRWT).  These inhibitors have not provided compelling clin. benefit in T790M-pos. patients, apparently because of dose-limiting toxicities assocd. with inhibition of EGFRWT.  Thus, there is an urgent clin. need for therapeutics that overcome T790M drug resistance while sparing EGFRWT.  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compds. that are EGFR mutant (EGFRmut) selective and have been designed to have low affinity for EGFRWT.  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFRWT.  Of all the compds. tested, compd. 3 displayed the best efficacy in EGFRL858R/T790M-driven tumors.  Compd. 3, now renamed CO-1686, is currently in a phase I/II clin. trial in patients with EGFRmut-advanced NSCLC that have received prior EGFR-directed therapy.  Mol Cancer Ther; 13(6); 1468-79. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Q725FacQMbVg90H21EOLACvtfcHk0ljFidxa-t5sPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Ojsro%253D&md5=c657fd56b98033bdc64e91b1dc338631</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520Irreversible%2520Mutant-Selective%2520EGFR%2520Inhibitors%2520That%2520Are%2520Wild-Type%2520Sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479%26doi%3D10.1158%2F1535-7163.MCT-13-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaligam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&author=P.+A.+Janneauthor=S.+S.+Ramaligamauthor=J.+C.+H.+Yangauthor=M.-J.+Ahnauthor=D.-W.+Kimauthor=S.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+activity+of+the+mutant-selective+EGFR+inhibitor+AZD9291+in+patients+%28pts%29+with+EGFR+inhibitor-resistant+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRamaligam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520activity%2520of%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520AZD9291%2520in%2520patients%2520%2528pts%2529%2520with%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor Resistant Non Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+J%C3%A4nneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor+Resistant+Non+Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2ebo_FPq-fDvHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor%2520Resistant%2520Non%2520Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivancos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lgJqkfgs_E5oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drilon, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span> </span><span class="NLM_article-title">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span> <span class="citation_source-journal">JAMA Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">982</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span><span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=982-984&author=H.+A.+Yuauthor=S.+K.+Tianauthor=A.+E.+Drilonauthor=L.+Borsuauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+Resistance+of+EGFR-Mutant+Lung+Cancer+to+a+T790M-Specific+EGFR+Inhibitor%3A+Emergence+of+a+Third+Mutation+%28C797S%29+in+the+EGFR+Tyrosine+Kinase+Domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520Resistance%2520of%2520EGFR-Mutant%2520Lung%2520Cancer%2520to%2520a%2520T790M-Specific%2520EGFR%2520Inhibitor%253A%2520Emergence%2520of%2520a%2520Third%2520Mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DJAMA%2520Oncology%26date%3D2015%26volume%3D7%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span> </span><span class="NLM_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6580</span><span class="NLM_x">–</span> <span class="NLM_lpage">6594</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6580-6594&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+Perspectives+on+the+Development+of+Small-Molecule+EGFR+Inhibitors+against+T790M-Mediated+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520Perspectives%2520on%2520the%2520Development%2520of%2520Small-Molecule%2520EGFR%2520Inhibitors%2520against%2520T790M-Mediated%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6580%26epage%3D6594%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkey, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, S.</span><span> </span><span class="NLM_article-title">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case History</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8877</span><span class="NLM_x">–</span> <span class="NLM_lpage">8895</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8877-8895&author=R.+A.+Healdauthor=B.+K.+Chanauthor=M.+C.+Bryanauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+Burdickauthor=E.+J.+Hananauthor=E.+Chanauthor=G.+Schaeferauthor=H.+Laauthor=H.+Purkeyauthor=J.+Knightauthor=I.+Yenauthor=P.+Jacksonauthor=K.+Bowmanauthor=K.+Mortaraauthor=M.+Lainchburyauthor=L.+Shaoauthor=R.+Elliottauthor=E.+Sewardauthor=S.+Malekauthor=S.+Schmidtauthor=S.+Siderisauthor=T.+P.+Heffronauthor=K.+Yeapauthor=Y.+Chenauthor=S.+Mann&title=Noncovalent+Mutant+Selective+Epidermal+Growth+Factor+Receptor+Inhibitors%3A+A+Lead+Optimization+Case+History&doi=10.1021%2Facs.jmedchem.5b01412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01412%26sid%3Dliteratum%253Aachs%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DPurkey%26aufirst%3DH.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DP.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DSeward%26aufirst%3DE.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DS.%26atitle%3DNoncovalent%2520Mutant%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitors%253A%2520A%2520Lead%2520Optimization%2520Case%2520History%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8877%26epage%3D8895%26doi%3D10.1021%2Facs.jmedchem.5b01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkey, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span> </span><span class="NLM_article-title">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10176</span><span class="NLM_x">–</span> <span class="NLM_lpage">10191</span><span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+Selective+and+Noncovalent+Diaminopyrimidine-Based+Inhibitors+of+Epidermal+Growth+Factor+Receptor+Containing+the+T790M+Resistance+Mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0lhNH5Zzbnxuag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520Selective%2520and%2520Noncovalent%2520Diaminopyrimidine-Based%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Containing%2520the%2520T790M%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kass, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzoli, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">19</span><span class="NLM_x">) </span> <span class="NLM_fpage">6322</span><span class="NLM_x">–</span> <span class="NLM_lpage">6328</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-11-1080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=21831955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6322-6328&issue=19&author=G.+R.+Oxnardauthor=Y.+Y.+Janjigianauthor=M.+E.+Arcilaauthor=C.+S.+Simaauthor=S.+L.+Kassauthor=G.+J.+Rielyauthor=W.+Paoauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=C.+G.+Azzoliauthor=V.+A.+Miller&title=Maintained+Sensitivity+to+EGFR+Tyrosine+Kinase+Inhibitors+in+EGFR-Mutant+Lung+Cancer+Recurring+after+Adjuvant+Erlotinib+or+Gefitinib&doi=10.1158%2F1078-0432.CCR-11-1080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Janjigian, Yelena Y.; Arcila, Maria E.; Sima, Camelia S.; Kass, Samantha L.; Riely, Gregory J.; Pao, William; Kris, Mark G.; Ladanyi, Marc; Azzoli, Christopher G.; Miller, Vincent A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6322-6328</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy.  However, there are conflicting findings regarding the potential benefit of adjuvant EGFR-TKI in patients with lung cancer harboring EGFR mutations.  To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI.  Exptl. Design: Patients with recurrent EGFR-mutant lung cancer following adjuvant TKI were identified using an Institutional Review Board-approved mechanism.  Recurrent cancer specimens were tested for resistance mutations.  Sensitivity to retreatment with EGFR-TKI was evaluated.  RESULTS: Twenty-two patients with cancers harboring an EGFR sensitizing mutation received adjuvant erlotinib or gefitinib for a median of 17 mo (range 1-37 mo).  T790M was more common in cancers which recurred while receiving TKI than in those which recurred after stopping TKI (67% vs. 0%, P = 0.011).  Fourteen patients who developed recurrence after stopping EGFR-TKI were retreated, with a median time to progression of 10 mo and radiog. response seen in 8 of 11 patients with evaluable disease (73%).  CONCLUSIONS: Recurrence of EGFR-mutant lung cancer after stopping adjuvant TKI should not preclude a trial of TKI retreatment; a phase II trial of erlotinib in this setting is underway.  Studies of adjuvant EGFR-TKI will underestimate the potential survival benefit of adjuvant TKI for patients with EGFR-mutant lung cancers if retreatment at recurrence is not given.  Clin Cancer Res; 17(19); 6322-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJi7hBJRf0QrVg90H21EOLACvtfcHk0lj6LP6LMOwC1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bO&md5=7c0d45eb3282cbe370abc0208de9371e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1080%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DKass%26aufirst%3DS.%2BL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DAzzoli%26aufirst%3DC.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DMaintained%2520Sensitivity%2520to%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520EGFR-Mutant%2520Lung%2520Cancer%2520Recurring%2520after%2520Adjuvant%2520Erlotinib%2520or%2520Gefitinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26issue%3D19%26spage%3D6322%26epage%3D6328%26doi%3D10.1158%2F1078-0432.CCR-11-1080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lj6LP6LMOwC1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: Further insights by examining carbo- and hetero-aromatic and aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+Further+insights+by+examining+carbo-+and+hetero-aromatic+and+aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lj6LP6LMOwC1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520Further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinhababu, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh-Bakht, S. C.</span><span> </span><span class="NLM_article-title">Metabolic Stability Screen for Drug Discovery Using Cassette Analysis and Column Switching</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.2174/187231207779814364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.2174%2F187231207779814364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=19356021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=67-72&author=J.+S.+Halladayauthor=S.+Wongauthor=S.+M.+Jafferauthor=A.+K.+Sinhababuauthor=S.+C.+Khojasteh-Bakht&title=Metabolic+Stability+Screen+for+Drug+Discovery+Using+Cassette+Analysis+and+Column+Switching&doi=10.2174%2F187231207779814364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability screen for drug discovery using cassette analysis and column switching</span></div><div class="casAuthors">Halladay, Jason S.; Wong, Susan; Jaffer, Sharmin M.; Sinhababu, Achintya K.; Khojasteh-Bakht, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In vitro metabolic stability assays are used to screen compds. for stability in the presence of various drug metabolizing enzymes, usually cytochrome P 450 in liver prepns. (e.g., liver microsomes).  High-throughput metabolic stability assays using pooling methods have been developed to keep pace with screening requirements at the lead ADME optimization stage.  In our lab., we have improved the metabolic stability assay using the cassette anal. method, column switching, and incorporated time saving techniques in method development to yield a robust method which reduces data turnaround time, increases compd. throughput, and maximizes mass spectrometer usage.  This method can det. metabolic stability using microsomes or hepatocytes from any species.  We describe our findings following incubation of 40 different compds. with human liver microsomes and anal. by the cassette and discrete anal. methods.  Similar metabolic stability results were obtained using the cassette anal. and discrete anal. method.  An overall 70% time savings was achieved by pooling four new compds. into one sample for method development/MS optimization, cassetting four samples into one sample to minimize the no. of injections on LC/MS/MS anal., and using a column switching system to analyze the samples, which results in a two-fold decrease in the LC/MS/MS anal. time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzVSm6sBe1bVg90H21EOLACvtfcHk0lgovHxM1NF78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D&md5=e00c66b3ca6a1eaee107c4eb81e07bf5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F187231207779814364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231207779814364%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DJaffer%26aufirst%3DS.%2BM.%26aulast%3DSinhababu%26aufirst%3DA.%2BK.%26aulast%3DKhojasteh-Bakht%26aufirst%3DS.%2BC.%26atitle%3DMetabolic%2520Stability%2520Screen%2520for%2520Drug%2520Discovery%2520Using%2520Cassette%2520Analysis%2520and%2520Column%2520Switching%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2007%26volume%3D1%26spage%3D67%26epage%3D72%26doi%3D10.2174%2F187231207779814364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rance, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wastall, P.</span><span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lgovHxM1NF78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':[],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Harald Engelhardt, Dietrich Böse, Mark Petronczki, Dirk Scharn, Gerd Bader, Anke Baum, Andreas Bergner, Eugene Chong, Sandra Döbel, Georg Egger, Christian Engelhardt, Peter Ettmayer, Julian E. Fuchs, Thomas Gerstberger, Nina Gonnella, Andreas Grimm, Elisabeth Grondal, Nizar Haddad, Barbara Hopfgartner, Roland Kousek, Mariusz Krawiec, Monika Kriz, Lyne Lamarre, Joyce Leung, Moriz Mayer, Nitinchandra D. Patel, Biljana Peric Simov, Jonathan T. Reeves, Renate Schnitzer, Andreas Schrenk, Bernadette Sharps, Flavio Solca, Heinz Stadtmüller, Zhulin Tan, Tobias Wunberg, Andreas Zoephel, <span class="NLM_string-name hlFld-ContribAuthor">Darryl B. McConnell</span>. </span><span class="cited-content_cbyCitation_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10272-10293. <a href="https://doi.org/10.1021/acs.jmedchem.9b01169" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStart%252BSelective%252Band%252BRigidify%25253A%252BThe%252BDiscovery%252BPath%252Btoward%252Ba%252BNext%252BGeneration%252Bof%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DEngelhardt%26aufirst%3DHarald%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14082019%26date%3D13112019%26date%3D05112019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eclair Venturini  Filho</span>, <span class="hlFld-ContribAuthor ">Erick M.C.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sergio  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sandro J.  Greco</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidines: Recent synthetic procedures and anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>92 </em>, 132256. <a href="https://doi.org/10.1016/j.tet.2021.132256" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132256%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAminopyrimidines%25253A%252BRecent%252Bsynthetic%252Bprocedures%252Band%252Banticancer%252Bactivities%26aulast%3DFilho%26aufirst%3DEclair%2BVenturini%26date%3D2021%26volume%3D92%26spage%3D132256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Cai</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Ullmann‐Ma
              Reaction: Development, Scope and Applications in Organic Synthesis
              †. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2020,</strong> <em>38 </em>
                                    (8)
                                     , 879-893. <a href="https://doi.org/10.1002/cjoc.202000075" title="DOI URL">https://doi.org/10.1002/cjoc.202000075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.202000075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.202000075%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DUllmann%2525E2%252580%252590Ma%252BReaction%25253A%252BDevelopment%25252C%252BScope%252Band%252BApplications%252Bin%252BOrganic%252BSynthesis%252B%2525E2%252580%2525A0%26aulast%3DCai%26aufirst%3DQian%26date%3D2020%26date%3D2020%26volume%3D38%26issue%3D8%26spage%3D879%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Stéphane  Gérard</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems: Three Heteroatoms 2:1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00021-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00021-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00021-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00021-4%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%25253A%252BThree%252BHeteroatoms%252B2%25253A1%26aulast%3DSapi%26aufirst%3DJanos%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liuxi  Chen</span>, <span class="hlFld-ContribAuthor ">Brian  Dean</span>, <span class="hlFld-ContribAuthor ">Hank  La</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaorong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective supercritical fluidic chromatography –mass spectrometry (SFC-MS) as a fast bioanalytical tool to assess chiral inversion in vivo and in vitro. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Mass Spectrometry</span><span> <strong>2019,</strong> <em>444 </em>, 116172. <a href="https://doi.org/10.1016/j.ijms.2019.06.008" title="DOI URL">https://doi.org/10.1016/j.ijms.2019.06.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijms.2019.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijms.2019.06.008%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Mass%2520Spectrometry%26atitle%3DStereoselective%252Bsupercritical%252Bfluidic%252Bchromatography%252B%2525E2%252580%252593mass%252Bspectrometry%252B%252528SFC-MS%252529%252Bas%252Ba%252Bfast%252Bbioanalytical%252Btool%252Bto%252Bassess%252Bchiral%252Binversion%252Bin%2525C2%2525A0vivo%252Band%252Bin%2525C2%2525A0vitro%26aulast%3DChen%26aufirst%3DLiuxi%26date%3D2019%26volume%3D444%26spage%3D116172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>, <span class="hlFld-ContribAuthor ">Vijay  Potluri</span>, <span class="hlFld-ContribAuthor ">Ranga R.  Pallepati</span>, <span class="hlFld-ContribAuthor ">Vishnu  Basetti</span>, <span class="hlFld-ContribAuthor ">Mallaiah  Keesara</span>, <span class="hlFld-ContribAuthor ">Ashok G.  Moghudula</span>, <span class="hlFld-ContribAuthor ">Pranab  Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1435-1439. <a href="https://doi.org/10.1016/j.bmcl.2019.04.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bgeneration%252Bof%252B1%25252C2-dithiolanes%252Bas%252Bexon%252B19%252Band%252Bexon%252B21%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DMansour%26aufirst%3DTarek%2BS.%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1435%26epage%3D1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shehnaz  Fatima</span>, <span class="hlFld-ContribAuthor ">Subhash Mohan  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2018,</strong> <em>38 </em>
                                    (4)
                                     , 299-306. <a href="https://doi.org/10.1080/10799893.2018.1494740" title="DOI URL">https://doi.org/10.1080/10799893.2018.1494740</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2018.1494740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2018.1494740%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DUnraveling%252Bstructural%252Brequirements%252Bof%252Bamino-pyrimidine%252BT790M%25252FL858R%252Bdouble%252Bmutant%252BEGFR%252Binhibitors%25253A%252B2D%252Band%252B3D%252BQSAR%252Bstudy%26aulast%3DFatima%26aufirst%3DShehnaz%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D4%26spage%3D299%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0001.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) T790M selective inhibitor <b>3</b>. Absolute stereochemistry of all asymmetric centers is as shown. (B) Overlay of a model of <i>N</i>-alkylsulfonylpyrazole design (green) with X-ray structure of resistance mutant-selective inhibitor <b>3</b> complexed with EGFR TMLR double mutant (ligand, orange; protein, cyan; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>). Predicted hydrogen bond interactions are shown as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of <b>7</b> complexed with EGFR TMLR double mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCX">5HCX</a>). Predicted hydrogen bond interactions are shown as yellow dashed lines. Interatom distance is indicated by dashed purple lines with values in Å.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) X-ray structure of <b>13</b> in EGFR TMLR double mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCY">5HCY</a>). Predicted hydrogen bond interactions are shown as yellow dashed lines. (B) X-ray structure of <b>13</b> in EGFR TMLR double mutant with interaction surface shown. Color of surface indicates element (pink = oxygen; cyan = nitrogen; gray = carbon).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>21</b> was administered orally to H1975 tumor-bearing mice with either a 50 or 100 mg/kg single dose. Tumors were collected at indicated times, and phosphorylation of EGFR, ERK, AKT was determined using commercially available MSD assays. Bars represent individual animals (four animals per group). Dotted line on the free plasma concentration plot shows the in vitro H1975 p-EGFR IC<sub>50</sub>. Error bars represent the mean ± SD. Plasma concentrations of <b>21</b> were measured using liquid chromatography–tandem mass spectrometry assay, and free concentration was calculated using <i>F</i><sub>u</sub> of 0.009.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 4-Amino-2-chloropyrimidine, Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 4 h, (26%); (b) <b>25</b>, <b>26</b>, or <b>27</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(Amphos)<sub>2</sub>Cl<sub>2</sub>, CH<sub>3</sub>CN, water, 100 °C, 3 h.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) For <b>25</b> and <b>26</b>, R-SO<sub>2</sub>Cl, NaH, DMF, rt, 5 h. (b) For <b>27</b>, bromomethylcyclopropane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 12 h (45%). (c) For <b>26</b>, 2-chloropyrimidin-4-amine, Na<sub>2</sub>CO<sub>3</sub>, Pd(Amphos)<sub>2</sub>Cl<sub>2</sub>, CH<sub>3</sub>CN, water, 100 °C, 2 h (85%).</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 2-Bromopropane, NaH, DMF, 0 °C to rt, 2 h (quant); (b) POCl<sub>3</sub>, DMF, rt, 2 h (80%); (c) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, water, <i>t</i>-BuOH, rt, 18 h (94%); (d) NH<sub>2</sub>R, HBTU, DIEA, DMF, rt, 40 min; (e) 4-amino-2-chloropyrimidine, Xantphos, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C, 6 h; (f) <b>26</b>, Na<sub>2</sub>CO<sub>3</sub>, Pd(Amphos)<sub>2</sub>Cl<sub>2</sub>, CH<sub>3</sub>CN, water, 100 °C, 1 h.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 2-Bromopropane, NaH, DMF, 0 °C to rt, 2 h (quant); (b) POCl<sub>3</sub>, DMF, rt, 2 h (80%); (c) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, water, <i>t</i>-BuOH, rt, 18 h (94%); (d) NH<sub>2</sub>R, HBTU, DIEA, DMF, rt, 40 min; (e) I<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h (quant); (f) 2-bromopropane, NaH, DMF, 0 °C to rt, 2 h (81%); (g) Pd(OAc)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>3</sub>OH, CO, 65 °C, 3 h (40%); (h) (i) (CH<sub>3</sub>)<sub>3</sub>SnOH, DCM, 60 °C, 4 h; (ii) NH<sub>4</sub>OH, HBTU, DIEA, DMF, rt, 20 min (25% over 2 steps); (i) 2-(4-methoxypiperidin-1-yl)pyrimidin-4-amine, chloro{[BrettPhos][2-(2-aminoethylphenyl]palladium(II)]}/[Brettphos] admixture, <i>t</i>-BuONa, <i>t</i>-BuOH, 120 °C, 3 h.</p></p></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) I<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt (quant); (b) 2-bromopropane, NaH, DMF, 0 °C to rt (44%); (c) benzophenone imine, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, 1,4-dioxane, 90 °C (58%); (d) <b>28</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C (50%); (e) NH<sub>2</sub>OH·HCl, NaOAc, rt (14%).</p></p></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) I<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) 2-bromopropane or 2-bromobutane, NaH, DMF, 0 °C to rt (quant); (c) HNR<sub>2</sub>, CuI, <span class="smallcaps smallerCapital">l</span>-proline, K<sub>2</sub>CO<sub>3</sub>, 90 °C, 3.5 h; (d) <b>28</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, XPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C.</p></p></figure><figure data-id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/medium/jm-2016-009954_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00995/20161007/images/large/jm-2016-009954_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00995&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) 4,4,5,5-Tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, KOAc, water, CH<sub>3</sub>CN, 100 °C, microwave (45%); (b) <b>28</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, XPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C (65%); (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, rt (56%).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28065" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28065" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Inhibition of EGFR signaling: all mutations are not created equal</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e377</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1371%2Fjournal.pmed.0020377" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e377&author=A.+F.+Gazdarauthor=J.+D.+Minna&title=Inhibition+of+EGFR+signaling%3A+all+mutations+are+not+created+equal&doi=10.1371%2Fjournal.pmed.0020377"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020377%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520EGFR%2520signaling%253A%2520all%2520mutations%2520are%2520not%2520created%2520equal%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De377%26doi%3D10.1371%2Fjournal.pmed.0020377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhillU1PjJErA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">–</span> <span class="NLM_lpage">1167</span><span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0ljc8UxXxQTY0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7241</span><span class="NLM_x">–</span> <span class="NLM_lpage">7244</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F0008-5472.CAN-04-1905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7241-7244&author=S.+Tracyauthor=T.+Mukoharaauthor=M.+Hansenauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=P.+A.+Janne&title=Gefitinib+induces+apoptosis+in+the+EGFRL858R+non-small-cell+lung+cancer+cell+line+H3255&doi=10.1158%2F0008-5472.CAN-04-1905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1905%26sid%3Dliteratum%253Aachs%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DGefitinib%2520induces%2520apoptosis%2520in%2520the%2520EGFRL858R%2520non-small-cell%2520lung%2520cancer%2520cell%2520line%2520H3255%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7241%26epage%3D7244%26doi%3D10.1158%2F0008-5472.CAN-04-1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Oncogene addiction: setting the stage for molecularly targeted cancer therapy</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3214</span><span class="NLM_x">–</span> <span class="NLM_lpage">3231</span><span class="refDoi"> DOI: 10.1101/gad.1609907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1101%2Fgad.1609907" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=3214-3231&author=S.+V.+Sharmaauthor=J.+Settleman&title=Oncogene+addiction%3A+setting+the+stage+for+molecularly+targeted+cancer+therapy&doi=10.1101%2Fgad.1609907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1101%2Fgad.1609907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1609907%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DOncogene%2520addiction%253A%2520setting%2520the%2520stage%2520for%2520molecularly%2520targeted%2520cancer%2520therapy%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D3214%26epage%3D3231%26doi%3D10.1101%2Fgad.1609907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Jackman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffredi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5267</span><span class="NLM_x">–</span> <span class="NLM_lpage">5273</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-09-0888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=19671843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5267-5273&author=D.+M.+Jackmanauthor=V.+A.+Millerauthor=L.+A.+Cioffrediauthor=B.+Y.+Yeapauthor=P.+A.+Janneauthor=G.+J.+Rielyauthor=M.+G.+Ruizauthor=G.+Giacconeauthor=L.+V.+Sequistauthor=B.+E.+Johnson&title=Impact+of+epidermal+growth+factor+receptor+and+KRAS+mutations+on+clinical+outcomes+in+previously+untreated+non-small+cell+lung+cancer+patients%3A+results+of+an+online+tumor+registry+of+clinical+trials&doi=10.1158%2F1078-0432.CCR-09-0888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online Tumor registry of clinical trials</span></div><div class="casAuthors">Jackman, David M.; Miller, Vincent A.; Cioffredi, Leigh-Anne; Yeap, Beow Y.; Jaenne, Pasi A.; Riely, Gregory J.; Ruiz, Marielle Gallegos; Giaccone, Giuseppe; Sequist, Lecia V.; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5267-5273</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated.  This study combines patient data from five trials in predominantly Western populations to assess the impact of EGFR and KRAS mutations on first-line therapy with an EGFR-tyrosine kinase inhibitor (TKI) and compare clin. vs. mol. predictors of sensitivity.  Chemotherapy-naive patients with advanced non-small cell lung cancer and known EGFR mutation status treated with erlotinib or gefitinib monotherapy as part of a clin. trial were eligible for inclusion.  Patients received daily erlotinib (150 mg) or gefitinib (250 mg) until disease progression or unacceptable toxicity.  Data were collected in a password-protected web database.  Clin. outcomes were analyzed to look for differences based on EGFR and KRAS genotypes, as well as clin. characteristics.  Patients (223) from five clin. trials were included.  Sensitizing EGFR mutations were assocd. with a 67% response rate, time to progression (TTP) of 11.8 mo, and overall survival of 23.9 mo.  Exon 19 deletions were assocd. with longer median TTP and overall survival compared with L858R mutations.  Wild-type EGFR was assocd. with poorer outcomes (response rate, 3%; TTP, 3.2 mo) irresp. of KRAS status.  No difference in outcome was seen between patients harboring KRAS transition vs. transversion mutations.  EGFR genotype was more effective than clin. characteristics at selecting appropriate patients for consideration of first-line therapy with an EGFR-TKI.  EGFR mutation status is assocd. with sensitivity to treatment with an EGFR-TKI in patients with advanced non-small cell lung cancer.  Patients harboring sensitizing EGFR mutations should be considered for first-line erlotinib or gefitinib. (Clin Cancer Res 2009;15(16):5267-73).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUmIDiCjeVvrVg90H21EOLACvtfcHk0ljc8UxXxQTY0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFeitLs%253D&md5=2d9669c6e4c396d632424c1c0190868c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0888%26sid%3Dliteratum%253Aachs%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCioffredi%26aufirst%3DL.%2BA.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DRuiz%26aufirst%3DM.%2BG.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DImpact%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520KRAS%2520mutations%2520on%2520clinical%2520outcomes%2520in%2520previously%2520untreated%2520non-small%2520cell%2520lung%2520cancer%2520patients%253A%2520results%2520of%2520an%2520online%2520tumor%2520registry%2520of%2520clinical%2520trials%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5267%26epage%3D5273%26doi%3D10.1158%2F1078-0432.CCR-09-0888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queralt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardenal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vivanco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Provencio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massuti, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Larriba, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Campelo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reguart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertran-Alamillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span> </span><span class="NLM_article-title">Screening for epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">958</span><span class="NLM_x">–</span> <span class="NLM_lpage">967</span><span class="refDoi"> DOI: 10.1056/NEJMoa0904554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa0904554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=19692684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=958-967&author=R.+Rosellauthor=T.+Moranauthor=C.+Queraltauthor=R.+Portaauthor=F.+Cardenalauthor=C.+Campsauthor=M.+Majemauthor=G.+Lopez-Vivancoauthor=D.+Islaauthor=M.+Provencioauthor=A.+Insaauthor=B.+Massutiauthor=J.+L.+Gonzalez-Larribaauthor=L.+Paz-Aresauthor=I.+Boverauthor=R.+Garcia-Campeloauthor=M.+A.+Morenoauthor=S.+Catotauthor=C.+Rolfoauthor=N.+Reguartauthor=R.+Palmeroauthor=J.+M.+Sanchezauthor=R.+Bastusauthor=C.+Mayoauthor=J.+Bertran-Alamilloauthor=M.+A.+Molinaauthor=J.+J.+Sanchezauthor=M.+Taron&title=Screening+for+epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1056%2FNEJMoa0904554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Screening for epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Gonzalez-Larriba, Jose Luis; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Moreno, Miguel Angel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Sanchez, Jose Miguel; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Molina, Miguel Angel; Sanchez, Jose Javier; Taron, Miquel; Cuello, M.; Pallares, C.; Lianes, P.; Remon, J.; Ibeas, R.; Martinez del Prado, P.; Angeles Sala, M.; Santander-Lobera, C.; Velez de Mendizabal, E.; Vinolas, N.; Terrasa, J.; Valdivia, J.; Diz, P.; Jimenez-Berlana, U.; Velasco-Ortiz de Taranco, A.; Ales Martinez, E.; Sanchez-Escribano, R.; Carrato, A.; Guillen-Ponce, C.; Mesia, C.; Antonio Macias, J.; Lopez-Brea, M.; Oramas, J.; Barneto, I.; Garrido, P.; Mayol, M. J.; Lopez, A.; Artal, A.; Saenz, A.; Hernando, S.; Cobo, M.; Blanco, R.; Bernabe, R.; Guillem, V.; Angel Munoz, M.; Maestu, I.; Salvatierra, A.; De Las Penas, R.; Alfaro, J.; Alberola, V.; Juan, O.; Martin, C.; Puertas, J.; Felip, E.; Gonzalez-Gonzalez, J. F.; Iglesias-Docampo, L.; Dorta, F. J.; Martinez-Aguillo, M.; Salgado, E.; Mesia, R.; Lastra-Aras, E.; Garcia-Munoz, J. P.; Lastra, R.; Alvarez, I.; Roig, J.; Oruezabal, J.; Poveda, A.; Lavernia, J.; Gutierrez, D.; Filipovich, E.; Aguiar, D.; Rodriguez, D.; Buxo, J.; Cardona, A. F.; Bes, P.; Paredes, A.; Tortorella, A. M.; Moreno, J. A.; Martinez-Garcia, J.; Alonso, J. L.; Lopez-Martin, A.; Echarri-Gonzalez, M. J.; Van Kooten, M.; Guerrero, A.; Domine, M.; Diaz, I.; Heras, L.; Garcia, R.; Anton, I.; Jarchum, G.; Bartolucci, R. E.; Lomas, M.; Rubiales, A.; Duque, J. L.; Escriva de Romani, S.; Barbeta, E.; Reina, J. J.; Castro, J.; Belda, C.; Vidal, J. M.; Trigo, J. M.; Vadell, C.; Zarba, J. J.; Esunza, P.; Garau, I.; Lopez-Pousa, A.; De la Gandara, I.; Widakowich, J.; Morales, S.; Martinez, M.; Luis, R.; de la Colina, M.; Calzas, J.; Garcia-Castro, I.; Ruiz, C.; Lopez-Criado, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">958-967</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer.  We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the assocn. between the mutations and the outcome of erlotinib treatment.  From Apr. 2005 through Nov. 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations.  The anal. was performed in a central lab.  Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment.  EGFR mutations were found in 350 of 2105 patients (16.6%).  Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P < 0.001 for all comparisons).  The mutations were deletions in exon 19 (62.2%) and L858R (37.8%).  Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 mo and 27 mo, resp.  The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P < 0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P = 0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P = 0.02).  The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%).  Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvZWnSnU_ScbVg90H21EOLACvtfcHk0lhcHEN8P7L0aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOqsL7M&md5=288ea35bd5201579d8c89ad6d7c4306a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904554%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCardenal%26aufirst%3DF.%26aulast%3DCamps%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DGonzalez-Larriba%26aufirst%3DJ.%2BL.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DCatot%26aufirst%3DS.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DBastus%26aufirst%3DR.%26aulast%3DMayo%26aufirst%3DC.%26aulast%3DBertran-Alamillo%26aufirst%3DJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DTaron%26aufirst%3DM.%26atitle%3DScreening%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D958%26epage%3D967%26doi%3D10.1056%2FNEJMoa0904554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span><span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lhcHEN8P7L0aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0ljOXdMuDHp93Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span><span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%22never+smokers%22+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%2522never%2520smokers%2522%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">May 20 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">8027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=8027&issue=May+20+Suppl.&author=P.+A.+Janneauthor=J.+H.+Schellensauthor=J.+A.+Engelmanauthor=S.+G.+Eckhardtauthor=R.+Millhamauthor=L.+J.+Denisauthor=C.+D.+Brittenauthor=S.+G.+Wongauthor=D.+S.+Bossauthor=D.+R.+Camidge&title=Preliminary+activity+and+safety+results+from+a+phase+I+clinical+trial+of+PF-00299804%2C+an+irreversible+pan-HER+inhibitor%2C+in+patients+%28pts%29+with+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520activity%2520and%2520safety%2520results%2520from%2520a%2520phase%2520I%2520clinical%2520trial%2520of%2520PF-00299804%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3DMay%252020%2520Suppl%26spage%3D8027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span><span class="refDoi"> DOI: 10.1200/JCO.2009.27.9414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2009.27.9414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0ljWm5ruG2U7pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083%26doi%3D10.1200%2FJCO.2009.27.9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.1038/nrc2947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer&doi=10.1038%2Fnrc2947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0ljWm5ruG2U7pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774%26doi%3D10.1038%2Fnrc2947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljWm5ruG2U7pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eb-xVCNcP5lSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+Disappointment%3A+Covalent+Inhibitors+to+Overcome+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0lgpjB91qa1z9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520Disappointment%253A%2520Covalent%2520Inhibitors%2520to%2520Overcome%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lgpjB91qa1z9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuboi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span> </span><span class="NLM_article-title">Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5769</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-06-0714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17020982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5764-5769&author=T.+Kosakaauthor=Y.+Yatabeauthor=H.+Endohauthor=K.+Yoshidaauthor=T.+Hidaauthor=M.+Tsuboiauthor=H.+Tadaauthor=H.+Kuwanoauthor=T.+Mitsudomi&title=Analysis+of+epidermal+growth+factor+receptor+gene+mutation+in+patients+with+non-small+cell+lung+cancer+and+acquired+resistance+to+gefitinib&doi=10.1158%2F1078-0432.CCR-06-0714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib</span></div><div class="casAuthors">Kosaka, Takayuki; Yatabe, Yasushi; Endoh, Hideki; Yoshida, Kimihide; Hida, Toyoaki; Tsuboi, Masahiro; Tada, Hirohito; Kuwano, Hiroyuki; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5764-5769</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Non-small cell lung cancers carrying activating mutations in the gene for the epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine kinase inhibitors.  However, most patients who initially respond subsequently experience disease progression while still on treatment.  Part of this "acquired resistance" is attributable to a secondary mutation resulting in threonine to methionine at codon 790 (T790M) of EGFR.  Exptl. Design: We sequenced exons 18 to 21 of the EGFR gene to look for secondary mutations in tumors with acquired resistance to gefitinib in 14 patients with adenocarcinomas.  Subcloning or cycleave PCR was used in addn. to normal sequencing to increase the sensitivity of the assay.  We also looked for T790M in pretreatment samples from 52 patients who were treated with gefitinib.  We also looked for secondary KRAS gene mutations because tumors with KRAS mutations are generally resistant to tyrosine kinase inhibitors.  RESULTS: Seven of 14 tumors had a secondary T790M mutation.  There were no other novel secondary mutations.  We detected no T790M mutations in pretreatment specimens from available five tumors among these seven tumors.  Patients with T790M tended to be women, never smokers, and carrying deletion mutations, but the T790M was not assocd. with the duration of gefitinib administration.  None of the tumors had an acquired mutation in the KRAS gene.  CONCLUSIONS: A secondary T790M mutation of EGFR accounted for half the tumors with acquired resistance to gefitinib in Japanese patients.  Other drug-resistant secondary mutations are uncommon in the EGFR gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZou5KHFws9bVg90H21EOLACvtfcHk0lhGy6ubkjLeCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVartbvL&md5=331c3e60cb4470484b418ee1b9a80674</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0714%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DTsuboi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DKuwano%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DAnalysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520gene%2520mutation%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%2520and%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5764%26epage%3D5769%26doi%3D10.1158%2F1078-0432.CCR-06-0714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Balak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouerfelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6494</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-06-1570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0lhGy6ubkjLeCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501%26doi%3D10.1158%2F1078-0432.CCR-06-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">Erlotinib activity in biochemical assays: wtEGFR <i>K</i><sub>i</sub> = 0.1 nM, EGFR(del<sub>746–750</sub>) <i>K</i><sub>i</sub> = 0.1 nM, EGFR(T790M/L858R) <i>K</i><sub>i</sub> = 123 nM, EGFR(T790M/del<sub>746–750</sub>) <i>K</i><sub>i</sub> = 95 nM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span><span class="refDoi"> DOI: 10.1073/pnas.0502860102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib&doi=10.1073%2Fpnas.0502860102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0lhGy6ubkjLeCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.0502860102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0ljq05bs3gtJtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: the new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1038/nrd2324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=17853901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+the+new+wave+of+BCR-ABL+inhibitors&doi=10.1038%2Fnrd2324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Flying under the radar: the new wave of BCR-ABL inhibitors</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia caused by the mutant BCR-ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs.  Quintas-Cardama and colleagues discuss novel BCR-ABL inhibitors that have the potential to overcome such resistance.  The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukemia (CML).  However, most patients with CML receiving imatinib still harbor mol. residual disease and some develop resistance assocd. with ABL kinase domain mutations.  The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clin. trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML.  Various medicinal chem. efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clin. trials, including against T315I mutants.  Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2DBi1E-INLVg90H21EOLACvtfcHk0ljq05bs3gtJtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ&md5=6a8692cd0405f77256df82ae7de21e18</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520the%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848%26doi%3D10.1038%2Fnrd2324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljq05bs3gtJtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Soria, J.-C.; Sequist, L. V.; Gadgeel, S.; Goldman, J.; Wakelee, H.; Varga, A.; Fidias, P.; Wozniak, A. J.; Neal, J. W.; Doebele, R. C.; Garon, E. B.; Jaw-Tsai, S.; Caunt, L.; Kaur, P.; Rolfe, L.; Allen, A.; Camidge, D. R.</span><span> </span><span class="NLM_article-title">First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)</span>. Presented at the 15th World Conference on Lung Cancer, Sydney, Australia,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.-C.+Soria&author=L.+V.+Sequist&author=S.+Gadgeel&author=J.+Goldman&author=H.+Wakelee&author=A.+Varga&author=P.+Fidias&author=A.+J.+Wozniak&author=J.+W.+Neal&author=R.+C.+Doebele&author=E.+B.+Garon&author=S.+Jaw-Tsai&author=L.+Caunt&author=P.+Kaur&author=L.+Rolfe&author=A.+Allen&author=D.+R.+Camidge&title=First-in-human+evaluation+of+CO-1686%2C+an+irreversible%2C+highly+selective+tyrosine+kinase+inhibitor+of+mutations+of+EGFR+%28activating+and+T790M%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DFirst-in-human%2520evaluation%2520of%2520CO-1686%252C%2520an%2520irreversible%252C%2520highly%2520selective%2520tyrosine%2520kinase%2520inhibitor%2520of%2520mutations%2520of%2520EGFR%2520%2528activating%2520and%2520T790M%2529%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Preliminary results from a phase I study with AZD9291</span>. Presented at the European Cancer Congress,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Ranson&title=Preliminary+results+from+a+phase+I+study+with+AZD9291"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DPreliminary%2520results%2520from%2520a%2520phase%2520I%2520study%2520with%2520AZD9291%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhqS_aZrAkpGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1479</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Ojsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+T.+T.+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+Vitro+and+In+Vivo+Characterization+of+Irreversible+Mutant-Selective+EGFR+Inhibitors+That+Are+Wild-Type+Sparing&doi=10.1158%2F1535-7163.MCT-13-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing</span></div><div class="casAuthors">Sjin, Robert Tjin Tham; Lee, Kwangho; Walter, Annette O.; Dubrovskiy, Aleksandr; Sheets, Michael; Martin, Thia St.; Labenski, Matthew T.; Zhu, Zhendong; Tester, Richland; Karp, Russell; Medikonda, Aravind; Chaturvedi, Prasoon; Ren, Yixuan; Haringsma, Henry; Etter, Jeff; Raponi, Mitch; Simmons, Andrew D.; Harding, Thomas C.; Niu, Deqiang; Nacht, Mariana; Westlin, William F.; Petter, Russell C.; Allen, Andrew; Singh, Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-1479</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approx. 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFRWT).  These inhibitors have not provided compelling clin. benefit in T790M-pos. patients, apparently because of dose-limiting toxicities assocd. with inhibition of EGFRWT.  Thus, there is an urgent clin. need for therapeutics that overcome T790M drug resistance while sparing EGFRWT.  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compds. that are EGFR mutant (EGFRmut) selective and have been designed to have low affinity for EGFRWT.  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFRWT.  Of all the compds. tested, compd. 3 displayed the best efficacy in EGFRL858R/T790M-driven tumors.  Compd. 3, now renamed CO-1686, is currently in a phase I/II clin. trial in patients with EGFRmut-advanced NSCLC that have received prior EGFR-directed therapy.  Mol Cancer Ther; 13(6); 1468-79. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Q725FacQMbVg90H21EOLACvtfcHk0lhqS_aZrAkpGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Ojsro%253D&md5=c657fd56b98033bdc64e91b1dc338631</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520Irreversible%2520Mutant-Selective%2520EGFR%2520Inhibitors%2520That%2520Are%2520Wild-Type%2520Sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479%26doi%3D10.1158%2F1535-7163.MCT-13-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaligam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small-cell lung cancer (NSCLC)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=8009&author=P.+A.+Janneauthor=S.+S.+Ramaligamauthor=J.+C.+H.+Yangauthor=M.-J.+Ahnauthor=D.-W.+Kimauthor=S.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=E.+Felipauthor=C.+Watkinsauthor=M.+Cantariniauthor=S.+Ghiorghiuauthor=M.+Ranson&title=Clinical+activity+of+the+mutant-selective+EGFR+inhibitor+AZD9291+in+patients+%28pts%29+with+EGFR+inhibitor-resistant+non-small-cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DRamaligam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DC.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DClinical%2520activity%2520of%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520AZD9291%2520in%2520patients%2520%2528pts%2529%2520with%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor Resistant Non Small-Cell Lung Cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+J%C3%A4nneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor+Resistant+Non+Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2ebQYtDj4o-B27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor%2520Resistant%2520Non%2520Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivancos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lhmrulDc1pSIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drilon, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span> </span><span class="NLM_article-title">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span> <span class="citation_source-journal">JAMA Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">982</span><span class="NLM_x">–</span> <span class="NLM_lpage">984</span><span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=982-984&author=H.+A.+Yuauthor=S.+K.+Tianauthor=A.+E.+Drilonauthor=L.+Borsuauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+Resistance+of+EGFR-Mutant+Lung+Cancer+to+a+T790M-Specific+EGFR+Inhibitor%3A+Emergence+of+a+Third+Mutation+%28C797S%29+in+the+EGFR+Tyrosine+Kinase+Domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520Resistance%2520of%2520EGFR-Mutant%2520Lung%2520Cancer%2520to%2520a%2520T790M-Specific%2520EGFR%2520Inhibitor%253A%2520Emergence%2520of%2520a%2520Third%2520Mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DJAMA%2520Oncology%26date%3D2015%26volume%3D7%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span> </span><span class="NLM_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6580</span><span class="NLM_x">–</span> <span class="NLM_lpage">6594</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6580-6594&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+Perspectives+on+the+Development+of+Small-Molecule+EGFR+Inhibitors+against+T790M-Mediated+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520Perspectives%2520on%2520the%2520Development%2520of%2520Small-Molecule%2520EGFR%2520Inhibitors%2520against%2520T790M-Mediated%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6580%26epage%3D6594%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkey, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, S.</span><span> </span><span class="NLM_article-title">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case History</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">8877</span><span class="NLM_x">–</span> <span class="NLM_lpage">8895</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8877-8895&author=R.+A.+Healdauthor=B.+K.+Chanauthor=M.+C.+Bryanauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+Burdickauthor=E.+J.+Hananauthor=E.+Chanauthor=G.+Schaeferauthor=H.+Laauthor=H.+Purkeyauthor=J.+Knightauthor=I.+Yenauthor=P.+Jacksonauthor=K.+Bowmanauthor=K.+Mortaraauthor=M.+Lainchburyauthor=L.+Shaoauthor=R.+Elliottauthor=E.+Sewardauthor=S.+Malekauthor=S.+Schmidtauthor=S.+Siderisauthor=T.+P.+Heffronauthor=K.+Yeapauthor=Y.+Chenauthor=S.+Mann&title=Noncovalent+Mutant+Selective+Epidermal+Growth+Factor+Receptor+Inhibitors%3A+A+Lead+Optimization+Case+History&doi=10.1021%2Facs.jmedchem.5b01412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01412%26sid%3Dliteratum%253Aachs%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DPurkey%26aufirst%3DH.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DP.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DSeward%26aufirst%3DE.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DS.%26atitle%3DNoncovalent%2520Mutant%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitors%253A%2520A%2520Lead%2520Optimization%2520Case%2520History%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8877%26epage%3D8895%26doi%3D10.1021%2Facs.jmedchem.5b01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkey, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span> </span><span class="NLM_article-title">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10176</span><span class="NLM_x">–</span> <span class="NLM_lpage">10191</span><span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+Selective+and+Noncovalent+Diaminopyrimidine-Based+Inhibitors+of+Epidermal+Growth+Factor+Receptor+Containing+the+T790M+Resistance+Mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0liU3VpMe7VUUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520Selective%2520and%2520Noncovalent%2520Diaminopyrimidine-Based%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Containing%2520the%2520T790M%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janjigian, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kass, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzoli, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">19</span><span class="NLM_x">) </span> <span class="NLM_fpage">6322</span><span class="NLM_x">–</span> <span class="NLM_lpage">6328</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1158%2F1078-0432.CCR-11-1080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=21831955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6322-6328&issue=19&author=G.+R.+Oxnardauthor=Y.+Y.+Janjigianauthor=M.+E.+Arcilaauthor=C.+S.+Simaauthor=S.+L.+Kassauthor=G.+J.+Rielyauthor=W.+Paoauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=C.+G.+Azzoliauthor=V.+A.+Miller&title=Maintained+Sensitivity+to+EGFR+Tyrosine+Kinase+Inhibitors+in+EGFR-Mutant+Lung+Cancer+Recurring+after+Adjuvant+Erlotinib+or+Gefitinib&doi=10.1158%2F1078-0432.CCR-11-1080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Janjigian, Yelena Y.; Arcila, Maria E.; Sima, Camelia S.; Kass, Samantha L.; Riely, Gregory J.; Pao, William; Kris, Mark G.; Ladanyi, Marc; Azzoli, Christopher G.; Miller, Vincent A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6322-6328</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy.  However, there are conflicting findings regarding the potential benefit of adjuvant EGFR-TKI in patients with lung cancer harboring EGFR mutations.  To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI.  Exptl. Design: Patients with recurrent EGFR-mutant lung cancer following adjuvant TKI were identified using an Institutional Review Board-approved mechanism.  Recurrent cancer specimens were tested for resistance mutations.  Sensitivity to retreatment with EGFR-TKI was evaluated.  RESULTS: Twenty-two patients with cancers harboring an EGFR sensitizing mutation received adjuvant erlotinib or gefitinib for a median of 17 mo (range 1-37 mo).  T790M was more common in cancers which recurred while receiving TKI than in those which recurred after stopping TKI (67% vs. 0%, P = 0.011).  Fourteen patients who developed recurrence after stopping EGFR-TKI were retreated, with a median time to progression of 10 mo and radiog. response seen in 8 of 11 patients with evaluable disease (73%).  CONCLUSIONS: Recurrence of EGFR-mutant lung cancer after stopping adjuvant TKI should not preclude a trial of TKI retreatment; a phase II trial of erlotinib in this setting is underway.  Studies of adjuvant EGFR-TKI will underestimate the potential survival benefit of adjuvant TKI for patients with EGFR-mutant lung cancers if retreatment at recurrence is not given.  Clin Cancer Res; 17(19); 6322-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJi7hBJRf0QrVg90H21EOLACvtfcHk0lhvuujp10-OCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ggs7bO&md5=7c0d45eb3282cbe370abc0208de9371e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1080%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DJanjigian%26aufirst%3DY.%2BY.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DKass%26aufirst%3DS.%2BL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DAzzoli%26aufirst%3DC.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DMaintained%2520Sensitivity%2520to%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520EGFR-Mutant%2520Lung%2520Cancer%2520Recurring%2520after%2520Adjuvant%2520Erlotinib%2520or%2520Gefitinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26issue%3D19%26spage%3D6322%26epage%3D6328%26doi%3D10.1158%2F1078-0432.CCR-11-1080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lhvuujp10-OCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: Further insights by examining carbo- and hetero-aromatic and aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+Further+insights+by+examining+carbo-+and+hetero-aromatic+and+aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lhvuujp10-OCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520Further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinhababu, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh-Bakht, S. C.</span><span> </span><span class="NLM_article-title">Metabolic Stability Screen for Drug Discovery Using Cassette Analysis and Column Switching</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.2174/187231207779814364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=10.2174%2F187231207779814364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=19356021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=67-72&author=J.+S.+Halladayauthor=S.+Wongauthor=S.+M.+Jafferauthor=A.+K.+Sinhababuauthor=S.+C.+Khojasteh-Bakht&title=Metabolic+Stability+Screen+for+Drug+Discovery+Using+Cassette+Analysis+and+Column+Switching&doi=10.2174%2F187231207779814364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability screen for drug discovery using cassette analysis and column switching</span></div><div class="casAuthors">Halladay, Jason S.; Wong, Susan; Jaffer, Sharmin M.; Sinhababu, Achintya K.; Khojasteh-Bakht, S. Cyrus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In vitro metabolic stability assays are used to screen compds. for stability in the presence of various drug metabolizing enzymes, usually cytochrome P 450 in liver prepns. (e.g., liver microsomes).  High-throughput metabolic stability assays using pooling methods have been developed to keep pace with screening requirements at the lead ADME optimization stage.  In our lab., we have improved the metabolic stability assay using the cassette anal. method, column switching, and incorporated time saving techniques in method development to yield a robust method which reduces data turnaround time, increases compd. throughput, and maximizes mass spectrometer usage.  This method can det. metabolic stability using microsomes or hepatocytes from any species.  We describe our findings following incubation of 40 different compds. with human liver microsomes and anal. by the cassette and discrete anal. methods.  Similar metabolic stability results were obtained using the cassette anal. and discrete anal. method.  An overall 70% time savings was achieved by pooling four new compds. into one sample for method development/MS optimization, cassetting four samples into one sample to minimize the no. of injections on LC/MS/MS anal., and using a column switching system to analyze the samples, which results in a two-fold decrease in the LC/MS/MS anal. time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzVSm6sBe1bVg90H21EOLACvtfcHk0lizM7iTNGhH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtleru74%253D&md5=e00c66b3ca6a1eaee107c4eb81e07bf5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F187231207779814364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231207779814364%26sid%3Dliteratum%253Aachs%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DJaffer%26aufirst%3DS.%2BM.%26aulast%3DSinhababu%26aufirst%3DA.%2BK.%26aulast%3DKhojasteh-Bakht%26aufirst%3DS.%2BC.%26atitle%3DMetabolic%2520Stability%2520Screen%2520for%2520Drug%2520Discovery%2520Using%2520Cassette%2520Analysis%2520and%2520Column%2520Switching%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2007%26volume%3D1%26spage%3D67%26epage%3D72%26doi%3D10.2174%2F187231207779814364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rance, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wastall, P.</span><span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lizM7iTNGhH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS','PDB','5CAS'); return false;">PDB: 5CAS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCX','PDB','5HCX'); return false;">PDB: 5HCX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCY','PDB','5HCY'); return false;">PDB: 5HCY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCZ','PDB','5HCZ'); return false;">PDB: 5HCZ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00995">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47454"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00995">10.1021/acs.jmedchem.6b00995</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Kinase selectivity profiling data for <b>21</b>; X-ray structure of <b>21</b> complexed with EGFR TMLR double mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCZ">5HCZ</a>); crystallographic data collection and refinement statistics; molecular modeling methods; in vivo xenograft pharmacodynamics studies materials and methods; experimental details for the preparation of all compounds; NMR data for key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_001.pdf">jm6b00995_si_001.pdf (874.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00995/suppl_file/jm6b00995_si_002.csv">jm6b00995_si_002.csv (2.62 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: TMLR/<b>3</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CAS">5CAS</a>; TMLR/<b>7</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCX">5HCX</a>; TMLR/<b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCY">5HCY</a>; TMLR/<b>21</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HCZ">5HCZ</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00995%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00995" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a63b9ebc93d88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
